

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1980:58712 CAPLUS

DOCUMENT NUMBER: 92:58712

TITLE: Study in nitrogen mustards, Part III. Synthesis of some 2-alkyl-3-aryl-4 (3H)-quinazolinone derivatives with nitrogen mustard moiety as possible antitumor agents

AUTHOR(S): Singh, Pritpal; Gupta, I. S.

CORPORATE SOURCE: Dep. Chem. Eng. Technol., Panjab Univ., Chandigarh, 160 014, India


SOURCE: J. Indian Chem. Soc. (1979), 56(1), 77-80

CODEN: JICSAH; ISSN: 0019-4522

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Title quinazolinones I [$Z = (CH_2)_n$ ($n = 0-2$), CHMe; R = e.g. $CH_2N(CH_2CH_2OH)_2$, $CH_2NHCH_2CH_2Br$; $R_1 = OH$, OMe, OEt] (32 compds.) and II [$Z = (CH_2)_n$ ($n = 1, 2$), CHMe; $R_2 = CH_2CH_2N(CH_2CH_2X)_2$ ($X = Br, Cl, OH$), $SO_2C_6H_4N(CH_2CH_2Cl)_2$] (10 compds.) were prepd. from N-acyl anthranilates


by condensing with anilines or hydrazides, resp. I and II contain mono or bifunctional nitrogen mustard groups attached to the quinazoline through an enzymatically-hydrolyzable linkage; they showed relatively low toxicity.

IT 72544-40-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and chlorination of)

RN 72544-40-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[3-[[bis(2-chloroethyl)amino]methyl]-4-hydroxyphenyl]-2-[[bis(2-hydroxyethyl)amino]methyl]- (9CI) (CA INDEX NAME)





IT 72497-16-6P 72497-17-7P 72509-85-4P
 72544-41-3P 72544-45-7P 72544-46-8P
 72544-47-9P 72544-48-0P 72544-49-1P
 72544-50-4P 72544-51-5P 72544-52-6P
 72544-53-7P 72544-54-8P 72544-55-9P
 72544-56-0P 72544-57-1P 72544-58-2P
 72544-59-3P 72544-60-6P 72544-61-7P
 72544-62-8P 72544-63-9P 72544-64-0P
 72544-65-1P 72544-66-2P 72544-67-3P
 72544-68-4P 72544-69-5P 72544-70-8P
 72544-72-0P 72544-73-1P 72544-74-2P
 72544-75-3P 72544-76-4P 72544-77-5P
 72544-78-6P 72544-79-7P 72544-80-0P
 72544-81-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)



RN 72497-16-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-[bis(2-chloroethyl)amino]ethyl]-3-[[[bis(2-chloroethyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 72497-17-7 CAPLUS



CN 4(3H)-Quinazolinone, 2-[1-[bis(2-chloroethyl)amino]ethyl]-3-[[[bis(2-chloroethyl)amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 72509-85-4 CAPLUS


CN 4(3H)-Quinazolinone, 2-[[bis(2-chloroethyl)amino]methyl]-3-[[[bis(2-

chloroethyl)amino]phenyl]sulfonyl)- (9CI) (CA INDEX NAME)




RN 72544-41-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[[bis(2-chloroethyl)amino]methyl]-3-[3-[[bis(2-chloroethyl)amino]methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 72544-45-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-[[bis(2-chloroethyl)amino]methyl]-3-[2-[[bis(2-hydroxyethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 72544-46-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-[bis(2-chloroethyl)amino]ethyl]-2-[[bis(2-chloroethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 72544-47-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-[2-[bis(2-bromoethyl)amino]ethyl]-2-[[bis(2-chloroethyl)amino]methyl]- (9CI) (CA INDEX NAME)




RN 72544-48-0 CAPLUS


CN 4(3H)-Quinazolinone, 2-[2-[bis(2-chloroethyl)amino]ethyl]-3-[2-[bis(2-hydroxyethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 72544-49-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2,3-bis[2-[bis(2-chloroethyl)amino]ethyl]- (9CI)
 (CA INDEX NAME)



RN 72544-50-4 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[bis(2-chloroethyl)amino]ethyl]-3-[3-[[bis(2-chloroethyl)amino]methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 72544-51-5 CAPLUS
 CN 4(3H)-Quinazolinone, 2-[1-[bis(2-chloroethyl)amino]ethyl]-3-[3-[[bis(2-chloroethyl)amino]methyl]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 72544-52-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[1-[bis(2-chloroethyl)amino]ethyl]-3-[3-[[bis(2-chloroethyl)amino]methyl]-4-ethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 72544-53-7 CAPLUS

CN 4(3H)-Quinazolinone, 3-[3-[[bis(2-bromoethyl)amino]methyl]-4-methoxyphenyl]-2-[1-[bis(2-chloroethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 72544-54-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-[1-[bis(2-chloroethyl)amino]ethyl]-3-[3-[(2-chloroethyl)amino]methyl]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 72544-55-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-[1-[bis(2-chloroethyl)amino]ethyl]-3-[3-[(2-bromoethyl)amino]methyl]-4-ethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 72544-56-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-[1-[bis(2-chloroethyl)amino]ethyl]-3-[4-[bis(2-chloroethyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 72544-57-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-[1-[bis(2-chloroethyl)amino]ethyl]-3-[2-[bis(2-chloroethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 72544-58-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[bis(2-chloroethyl)amino]-2-[1-[bis(2-chloroethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 72544-59-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[[bis(2-chloroethyl)amino]methyl]-3-[3-[[bis(2-hydroxyethyl)amino]methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 72544-60-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[[bis(2-chloroethyl)amino]methyl]-3-[3-[[2-bromoethyl)amino]methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 72544-61-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-[[bis(2-chloroethyl)amino]methyl]-3-[3-[[bis(2-hydroxyethyl)amino]methyl]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 72544-62-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-[[bis(2-chloroethyl)amino]methyl]-3-[3-[[bis(2-chloroethyl)amino]methyl]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 72544-63-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-[[bis(2-chloroethyl)amino]methyl]-3-[3-[[2-(2-chloroethoxy)ethyl]amino]methyl]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 72544-64-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-[[bis(2-chloroethyl)amino]methyl]-3-[3-[[2-(2-bromoethyl)amino]methyl]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 72544-65-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-[[bis(2-chloroethyl)amino]methyl]-3-[3-[[bis(2-hydroxyethyl)amino]methyl]-4-ethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 72544-66-2 CAPLUS

CN 4(3H)-Quinazolinone, 2-[[bis(2-chloroethyl)amino]methyl]-3-[3-[[bis(2-chloroethyl)amino]methyl]-4-ethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 72544-67-3 CAPLUS

CN 4(3H)-Quinazolinone,
3-[3-[[bis(2-bromoethyl)amino]methyl]-4-ethoxyphenyl]-
2-[[bis(2-chloroethyl)amino]methyl]- (9CI) (CA INDEX NAME)

RN 72544-68-4 CAPLUS


CN 4(3H)-Quinazolinone, 2-[[bis(2-chloroethyl)amino]methyl]-3-[4-ethoxy-3-

[[(2-hydroxyethyl) amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 72544-69-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[[bis(2-chloroethyl)amino]methyl]-3-[3-[[(2-chloroethyl)amino]methyl]-4-ethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 72544-70-8 CAPLUS

CN 4(3H)-Quinazolinone, 2-[[bis(2-chloroethyl)amino]methyl]-3-[3-[[(2-bromoethyl)amino]methyl]-4-ethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 72544-72-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-[[bis(2-chloroethyl)amino]ethyl]-3-[3-[[bis(2-hydroxyethyl)amino]methyl]-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)



RN 72544-73-1 CAPLUS


CN 4(3H)-Quinazolinone, 2-[2-[bis(2-chloroethyl)amino]ethyl]-3-[3-[[bis(2-chloroethyl)amino]methyl]-4-hydroxyphenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 72544-74-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-[3-[[bis(2-bromoethyl)amino]methyl]-4-hydroxyphenyl]-2-[2-bis(2-chloroethyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 72544-75-3 CAPLUS


CN 4(3H)-Quinazolinone, 2-[2-[bis(2-chloroethyl)amino]ethyl]-3-[3-[[bis(2-chloroethyl)amino]methyl]-4-methoxyphenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 72544-76-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-[bis(2-chloroethyl)amino]ethyl]-3-[3-[[2-bromoethyl)amino]methyl]-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 72544-77-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-[bis(2-chloroethyl)amino]ethyl]-3-[3-[[bis(2-hydroxyethyl)amino]methyl]-4-ethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 72544-78-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-[bis(2-chloroethyl)amino]ethyl]-3-[3-[[bis(2-chloroethyl)amino]methyl]-4-ethoxyphenyl]- (9CI) (CA INDEX NAME)




RN 72544-79-7 CAPLUS

CN 4(3H)-Quinazolinone,
3-[3-[[bis(2-bromoethyl)amino]methyl]-4-ethoxyphenyl]-
2-[2-[bis(2-chloroethyl)amino]ethyl]- (9CI) (CA INDEX NAME)




RN 72544-80-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-[bis(2-chloroethyl)amino]ethyl]-3-[3-[[2-chloroethyl)amino)methyl]-4-ethoxyphenyl]- (9CI) (CA INDEX NAME)



RN 72544-81-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-[2-[bis(2-chloroethyl)amino]ethyl]-3-[3-[[2-bromoethyl)amino)methyl]-4-ethoxyphenyl]- (9CI) (CA INDEX NAME)




=> d his

(FILE 'HOME' ENTERED AT 15:38:26 ON 13 MAR 2001)


ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 57 CAPLUS COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 1999:673737 CAPLUS
 DOCUMENT NUMBER: 132:35672
 TITLE: Synthesis and biological activity of some
 2-substituted quinazolin-4-ones
 AUTHOR(S): Spirkova, K.; Stankovsky, S.; Mrvova, A.; Cipak, L'.
 CORPORATE SOURCE: Department of Organic Chemistry, Faculty of Chemical
 Technology, Slovak University of Technology,
 Bratislava, SK-812 37, Slovakia
 SOURCE: Chem. Pap. (1999), 53(4), 272-275
 CODEN: CHPAEG; ISSN: 0366-6352
 PUBLISHER: Slovak Academic Press Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 132:35672
 GI




I

AB The nonclassical antifolates, e.g. 2-morpholinomethyl-3H-quinazolin-4-one
 (I), have been prepd. by nucleophilic substitution of bromine in
 2-bromomethyl-3H-quinazolin-4-one by nitrogen and oxygen nucleophiles.
 IR and 1H NMR spectra, 13C NMR data of selected compds., basic antibacterial
 and cytotoxic activities are presented.
 IT **252570-57-3P**
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic
 preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. and biol. activity of quinazolinones as antibacterial and
 antitumor agents)
 RN 252570-57-3 CAPLUS
 CN 4(1H)-Quinazolinone, 2-[(dimethylamino)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10
 REFERENCE(S): (1) Gupta, C; J Med Chem 1968, V11, P392 CAPLUS
 (2) Horakova, K; Neoplasma 1988, V35, P169 CAPLUS



→ L8 ANSWER 24 OF 57 CAPLUS COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 1996:273045 CAPLUS
 DOCUMENT NUMBER: 124:331723
 TITLE: Quinazolythiazoles as CNS acting agents
 AUTHOR(S): Pandey, Vinod Kumar; Gupta, Manjusha
 CORPORATE SOURCE: Dep. Chem., Univ. Lucknow, Lucknow, 226 007, India
 SOURCE: Acta Pharm. (Zagreb) (1996), 46(1), 51-9
 CODEN: ACPHEE; ISSN: 1330-0075
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Treatment of anthranilic acid with an aryl acid chloride in the presence of pyridine yielded 2-aryl-4-oxo-3,1-benzoxazine which on treatment with p-aminoacetophenone in the presence of anhyd. pyridine afforded 2-aryl-3-(p-acetylphenyl)-3,4-dihydro-4-oxo-quinazolines (I) in excellent yields. Reaction of I with thiosemicarbazide in the presence of ethanol resulted in 2-aryl-4-oxo-3,4-dihydro-quinazolyl-3-[p-(acetophenone thiosemicarbazones)] (II) in the yields ranging from 60-65%. Reaction of II with acetophenone and iodine in glacial acetic acid yielded 2-aryl-4-oxo-3,4-dihydroquinazolyl-3-[p-(5'-phenyl-3'-thiazolyl)acetophenoneazines] in moderate yields; these compds. showed psychotropic activity without any toxicity (ALD50 values were > 1000 mg kg⁻¹). Most of the compds. were also found to possess writhing effect while only one compd. exhibited hyperthermic activity. Four of such compds. showed promising CNS stimulant activity and two compds. were found

to exert CNS depressant activity.

IT 176772-15-9P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. and structure activity of quinazolythiazoles as central nervous system agents)



RN 176772-15-9 CAPLUS

CN Benzamide,

N-[[3-(4-acetylphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl)methyl]-
 (9CI) (CA INDEX NAME)



AUTHOR(S): arylcarbamoylmethoxyphenyl-4-(3H)-quinazolones
 CORPORATE SOURCE: Parasharya, P. M.; Soni, V. C.; Parikh, A. R.
 SOURCE: Chem. Dep., Saurashtra Univ., Rajkot, 360 005, India
 J. Inst. Chem. (India) (1992), 64(6), 238-41
 CODEN: JOICA7; ISSN: 0020-3254
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Some new 4(3H)-quinazolinone derivs., I and II, having N-arylaminoethyl/N-alkylaminomethyl/N-arylaminoethyl group at C(2) and p-hydroxyphenyl/p-anisyl/p-arylaminoacyloxyphenyl/p-(N-arylcarbamoylmethoxy)phenyl group at C(3) were prepd. I and II showed moderate antimicrobial activity (no data). Structures of I and II were confirmed by IR spectra and elemental anal.

IT 156672-31-0P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. and antimicrobial activity of)

RN 156672-31-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(phenylamino)methyl]- (9CI)
 (CA INDEX NAME)



→ L8 ANSWER 27 OF 57 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1994:508675 CAPLUS

DOCUMENT NUMBER: 121:108675

TITLE: 4(3H)-Quinazolones. Part I:

2-Alkyl/arylaminoethyl-3-

p-hydroxy/methoxyphenyl-4(3H)-quinazolones

AUTHOR(S): Parasharya, P. M.; Parikh, A. R.


CORPORATE SOURCE: Chem. Dep., Saurashtra Univ., Rajkot, 360 005, India

SOURCE: J. Inst. Chem. (India) (1992), 64(5), 184-5

CODEN: JOICA7; ISSN: 0020-3254

DOCUMENT TYPE: Journal

LANGUAGE: English
GI




AB The title compds. I (X = OH, OMe; R = alkyl, aryl) were prepd. by amination of the 2-(bromomethyl) derivs. and tested for antibacterial activity. Some I showed remarkable antibacterial activity.

IT **156672-31-0P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); **BIOL (Biological study)**; PREP (Preparation) (prepn. and antibacterial activity of)

RN 156672-31-0 CAPLUS

CN 4(3H)-Quinazolinone, 3-(4-hydroxyphenyl)-2-[(phenylamino)methyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 28 OF 57 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1992:591731 CAPLUS

DOCUMENT NUMBER: 117:191731

TITLE: Synthesis and evaluation of 2-pyridinone derivatives as HIV-1-specific reverse transcriptase inhibitors. 2. Analogs of 3-aminopyridin-2(1H)-one

AUTHOR(S): Saari, Walfred S.; Wai, John S.; Fisher, Thorsten E.; Thomas, Craig M.; Hoffman, Jacob M.; Rooney, Clarence S.; Smith, Anthony M.; Jones, James H.; Bamberger, Dona L.; et al.


CORPORATE SOURCE: Dep. Med. Chem., Merck Res. Lab., West Point, PA, 19486-0004, USA

SOURCE: J. Med. Chem. (1992), 35(21), 3792-802
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

GI




AB A series of nonnucleoside 3-aminopyridine-2(1H)-one derivs. was synthesized and evaluated for HIV-1 RT inhibitory properties. Several analogs proved to be potent and highly selective antagonists with in vitro IC50 values as low as 19 nM in the enzyme assay using rC.cntdot.dG as template.cntdot.primers. Two compds. from this series, benzoxazolylmethylaminopyridinones I (R = Me, Cl) inhibited the spread of HIV-1 IIIB infection by 95% in MT4 cell culture at concns. of 25-50 nM and were selected for clin. trials as antiviral agents.

IT **143707-89-5P**
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); **BIOL (Biological study)**; PREP (Preparation)
 (prepn. and virucidal activity of)

RN 143707-89-5 CAPLUS

CN 4(1H)-Quinazolinone, 2-[[5-ethyl-1,2-dihydro-6-methyl-2-oxo-3-pyridinyl)amino]methyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 29 OF 57 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1991:505457 CAPLUS

DOCUMENT NUMBER: 115:105457

TITLE: Antitubercular agents. LVI. The problem of optimal lipophilicity of antitubercular thiohydrazides

AUTHOR(S): Waisser, K.

CORPORATE SOURCE: Farm. Fak., Univ. Karlovy, Hradec Kralove, Czech.


SOURCE: Cesk. Farm. (1991), 40(3), 106-7
 CODEN: CKFRAY; ISSN: 0009-0530

DOCUMENT TYPE: Journal


LANGUAGE: Czech

AB QSAR equations are derived from MIC data and partition chromatog. for detg. the optimal lipophilicity of thiohydrazides. Because of their

(prepn. and bactericidal activity of)
 RN 134989-51-8 CAPLUS
 CN 4(3H)-Quinazolinone,
 2-[[[4-[4,5-dihydro-4-[(4-hydroxyphenyl)methylene]-5-
 oxo-2-phenyl-1H-imidazol-1-yl]phenyl]amino]methyl]-3-phenyl- (9CI) (CA
 INDEX NAME)




→ L8 ANSWER 31 OF 57 CAPLUS COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 1991:122242 CAPLUS
 DOCUMENT NUMBER: 114:122242
 TITLE: Non-steroidal antiinflammatory agents. III: Synthesis of pyrazole derivatives of 4(3H)-quinazolinones
 AUTHOR(S): Farghaly, Ahmed M.; Chaaban, Ibrahim; Khalil, Mounir A.; Bekhit, Adnan A.
 CORPORATE SOURCE: Fac. Pharm., Univ. Alexandria, Alexandria, Egypt
 SOURCE: Alexandria J. Pharm. Sci. (1990), 4(1), 52-6
 CODEN: AJPSES
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 114:122242
 GI




AB Several groups of compds. were synthesized having a pyrazole or pyrazoline moiety attached to 4(3H)-quinazolinone at the 2- or 3-position either directly or through different linkages. The linkages include methinamino, ethenyl, iminomethyl, aminomethyl or methinehydrazino grouping. Thus, acetantranyl (I) was treated with aminoantipyrine II to give 4(3H)-quinazolinone III. The antiinflammatory activity of representative examples of the products is reported.

IT **132111-60-5P**
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); **BIOL (Biological study)**; PREP (Preparation)
 (prepn. and antiinflammatory activity of)
 RN 132111-60-5 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(4-chlorophenyl)-2-[[(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)amino]methyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 32 OF 57 CAPLUS COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 1990:400196 CAPLUS
 DOCUMENT NUMBER: 113:196
 TITLE: Tuberculostatics. Part 49. Thiohydrazides, potential tuberculostatics
 AUTHOR(S): Waisser, K.; HOUNGBEDJI, N.; ODLEROVA, Z.; THIEL, W.; MAYER, R.
 CORPORATE SOURCE: Fac. Pharm., Univ. Charles, Hradec Kralove, 50165, Czech.
 SOURCE: Pharmazie (1990), 45(2), 141-2
 CODEN: PHARAT; ISSN: 0031-7144
 DOCUMENT TYPE: Journal
 LANGUAGE: French
 GI





I

AB Four thiohydrazides (I; X = NH, O, S, or CONH) had differing degrees of antimycobacterial activity in vitro. When the most active compd., I (X = O), was tested in tuberculous mice, there was a high mortality rate after a few days of treatment, perhaps due to interaction of the thiohydrazide group with the oxo group of transaminases. I therefore cannot be used as drugs, and their pharmacol. study has been abandoned.

IT **127627-24-1**
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); **BIOL (Biological study)**; USES (Uses)
 (tuberculostatic activity of)
 RN 127627-24-1 CAPLUS

DOCUMENT TYPE: CODEN: IJSBDB; ISSN: 0376-4699
 LANGUAGE: Journal
 OTHER SOURCE(S): English
 CASREACT 108:112384
 GI




AB Quinazolinecarbohydrazides I [R1 = H, Me, OMe, halo, and R2 = H; R1R2 = (CH2O2)] were prepd. from the resp. anthranilamides by cyclocondensation with EtO2CCO2Et and subsequent amidation with N2H4; I showed antitubercular activity. Also prepd. were tosyl derivs. II.

IT **34632-71-8P**
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); USES (Uses)
 (prepn. and antitubercular activity of)

RN 34632-71-8 CAPLUS

CN 2-Quinazolinecarboxylic acid, 1,4-dihydro-4-oxo-, hydrazide (9CI) (CA INDEX NAME)



→ L8 ANSWER 36 OF 57 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1987:207516 CAPLUS


DOCUMENT NUMBER: 106:207516

TITLE: Synthesis and anticonvulsant activity of some new 4(3H)-quinazalone derivatives

AUTHOR(S): El-Nasser Ossman, Abdel Rahman; El-Sayed Barakat, Saber

CORPORATE SOURCE: Fac. Pharm., Al-Azhar Univ., Cairo, Egypt

SOURCE: Arch. Pharm. Chemi, Sci. Ed. (1986), 14(2), 37-43
 CODEN: AVPCCS; ISSN: 0302-248X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



I, Z=NHC₆H₄SO₂NH₂-4

II, Z=Br


AB Some new 2,3-disubstituted-4(3H)-quinazolones (I, X and Y = H or Br, and
 R = H, Br, Cl or NO₂) as potential anticonvulsants were prepd. by the
 N-bromosuccinimide bromination of 2-methyl-3-phenyl-4(3H)-quinazolones
 followed by the reaction of the resulting bromomethyl derivs. (II) with
 sulfanilamide [63-74-1].

IT 108282-55-9P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); USES (Uses)
 (prepn. and anticonvulsant activity of)

RN 108282-55-9 CAPLUS

CN Benzenesulfonamide, 4-[[(3,4-dihydro-4-oxo-3-phenyl-2-
 quinazolinyl)methyl]amino]- (9CI) (CA INDEX NAME)



➤L8 ANSWER 37 OF 57 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1986:497416 CAPLUS


DOCUMENT NUMBER: 105:97416

TITLE: Synthesis and biological activities of certain
 derivatives of 3-aryl-4(3H)-quinazolinones. Part II

AUTHOR(S): Rao, A. Devender; Shankar, C. Ravi; Reddy, P.
 Bhagavan; Reddy, V. Malla

CORPORATE SOURCE: Coll. Pharm. Sci., Kakatiya Univ., Warangal, 506 009,
 India

SOURCE: J. Indian Chem. Soc. (1985), 62(3), 234-7
 CODEN: JICSAH; ISSN: 0019-4522



AB The title quinazolinones I (R = H, Me, Cl, OMe, OEt) were prepd. by treating 2-aminobenzothiazoles with 3,5-dichloroacetylanthranilic acid followed by refluxing the product with paraformaldehyde and Et₂NH.HCl. The fungicidal activity of I against *Aspergillus fumigatus* and *Alternaria alternata* depended on their structure. Best inhibition of *Alternaria* growth was obtained with I (R = 4-Cl) [98256-90-7] and I (R = 6-OMe) [98256-92-9]; with *Aspergillus* highest inhibition was obtained with I (R

=

5-Cl) [98256-91-8].


IT **98256-83-8P**

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); **BIOL (Biological study)**; PREP (Preparation); USES (Uses)

(prepn. and fungicidal activity of, structure in relation to)

RN 98256-83-8 CAPLUS

CN 4(3H)-Quinazolinone, 3-(2-benzothiazolyl)-6,8-dichloro-2-[2-(diethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

→ L8 ANSWER 42 OF 57 CAPLUS COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 1985:142800 CAPLUS
 DOCUMENT NUMBER: 102:142800
 TITLE: Acetylcholinesterase and succinate dehydrogenase inhibitory activity of trisubstituted quinazolones
 AUTHOR(S): Kumar, Pradeep; Ahmad, S.; Bhargava, K. P.; Shanker, K.
 CORPORATE SOURCE: Dep. Pharmacol. Ther., King George's Med. Coll., Lucknow, India
 SOURCE: Indian Drugs (1985), 22(4), 202-4

DOCUMENT TYPE:
LANGUAGE:
GI

CODEN: INDRBA; ISSN: 0019-462X
Journal
English



AB The inhibitory activities of 16 2-(arylalkylamino)methyl-3-aryl-6-substituted-4-(3H)quinazolinones I ($R_1 = H, Cl, \text{ or } OMe$; $R_2 = Cl, Me, \text{ or } OMe$;

$X = H \text{ or } I$; $n = 1 \text{ or } 2$) against acetylcholinesterase [9000-81-1] and succinate dehydrogenase [9002-02-2] were detd. Structure-activity relations are discussed.

IT 19062-63-6D, derivs.


RL: BIOL (Biological study)

(acetylcholinesterase and succinic dehydrogenase inhibition by)

RN 19062-63-6 CAPLUS

CN 4(3H)-Quinazolinone, 3-phenyl-2-[(2-phenylethyl)amino]methyl- (9CI)
(CA

INDEX NAME)



L8 ANSWER 43 OF 57 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1985:45864 CAPLUS

DOCUMENT NUMBER: 102:45864

TITLE: Synthesis and antiinflammatory activity of
2-substituted-phenethyl-3-substituted-phenyl-4(3H)-
quinazolinones

AUTHOR(S): Singh, Inder Pal; Saxena, A. K.; Sinha, J. N.;
Bhargava, K. P.; Shanker, K.

CORPORATE SOURCE: Dep. Pharmacol. Ther., King George's Med. Coll.,
Lucknow, 226 003, India



SOURCE: Indian J. Chem., Sect. B (1984), 23B(6), 592-4
CODEN: IJSBDB; ISSN: 0376-4699

DOCUMENT TYPE: Journal


LANGUAGE: English

GI

→ ACCESSION NUMBER: 1982:6681 CAPLUS
 DOCUMENT NUMBER: 96:6681
 TITLE: Synthesis of some new 4(3H)-quinazolinones as potential fungicides
 AUTHOR(S): Chaurasia, M. R.; Sharma, Surendra K.; Kumar, Sunil
 CORPORATE SOURCE: Dep. Chem., D.A.V. Coll., Dehra Dun, 248 001, India
 SOURCE: Curr. Sci. (1981), 50(19), 841-3
 CODEN: CUSCAM; ISSN: 0011-3891
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Benzothiazolylquinazolines I (R = H, 4-, 5-, 6-Me, 4-, 5-, 6-Cl, 6-MeO, 6-EtO, R1 = H, Br) were prepd. in 32-71% yields by cyclocondensation of
 II in the presence of an appropriate 2-aminobenzimidazole to give intermediates (no data) which were condensed with CH2O and Et2NH.HCl. I inhibited *Aspergillus niger* and *Draschlera australiensis*.
 IT **80144-66-7P**
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); **BIOL (Biological study)**; PREP (Preparation) (prepn. and fungicidal activity of)
 RN 80144-66-7 CAPLUS
 CN 4(3H)-Quinazolinone, 3-(2-benzothiazolyl)-2-[2-(diethylamino)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




⊙ HCl

L8 ANSWER 48 OF 57 CAPLUS COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 1981:84054 CAPLUS
 DOCUMENT NUMBER: 94:84054
 TITLE: Quinazolinone derivatives of etiological interest.
 II. Synthesis and antibacterial activity of certain
 3-aryl-2-(.beta.-arylsulfonylhydrazinomethyl)-4(3H)-
 quinazolinones
 AUTHOR(S): Abdel-Aleem, A. M.; Abdel-Ghaffar, A. F.
 CORPORATE SOURCE: Fac. Pharm. Microbiol., Assiut Univ., Assiut, Egypt
 SOURCE: Indian J. Pharm. Sci. (1980), 42(3), 79-81
 CODEN: IJSIDW
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Quinazolinones I (R = 3-MeC6H4, 4-MeOC6H4, 4-ClC6H4, R1 = H, Me, NHAc, Br, Cl, NO2; R = Ph, 4-MeC6H4, 3-MeOC6H4, 4-BrC6H4, 3-ClC6H4, 4-EtO2CC6H4, 2-pyridyl, R1 = H) were prepd. by treating the chloromethylquinazolinones with 4-R1C6H4SO2NHNH2. I had bactericidal activity less than that of sulfanilamide.
 IT **76534-78-6P**
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); **BIOL (Biological study)**; PREP (Preparation) (prepn. and bactericidal activity of)
 RN 76534-78-6 CAPLUS
 CN Benzenesulfonic acid, 2-[(3,4-dihydro-4-oxo-3-phenyl-2-quinazolinyl)methyl]hydrazide (9CI) (CA INDEX NAME)



L8 ANSWER 49 OF 57 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1980:426374 CAPLUS

DOCUMENT NUMBER: 93:26374

TITLE: Studies on biologically active halogenated compounds.
II. Chemical modifications of

6-amino-2-fluoromethyl-

3-[o-tolyl]-4[3H]-quinazolinone and the CNS depressant

activities of related compounds

AUTHOR(S) : Tani, Junichi; Yamada, Yoshihisa; Ochiai, Takashi;
Ishida, Ryuichi; Inoue, Ichizo; Oine, Toyonari

CORPORATE SOURCE: Res. Lab., Tanabe Seiyaku Co., Ltd., Osaka, 532, Japan

SOURCE: Chem. Pharm. Bull. (1979), 27(11), 2675-87

CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A no. of derivs. of 6-amino-2-fluoromethyl-3-(o-tolyl)-4(3H)-quinazolinone (6-aminomethaqualone), a potent muscle relaxant, were prepd. and screened in terms of the loss of righting reflex test and the rotating rod test in mice. Several derivs. with addnl. F substitution or with repositioning of

the F atom exhibited high activities. Other structural modification included acylation, carbamoylation, and alkoxy carbonylation of the

6-amino group, hydroxylation at the 3-tolyl group, and replacement of the F atom at the 2-fluoromethyl group by O, N and S nucleophiles; these modification

all resulted in loss of activity.

IT 73832-37-8P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);


PREP (Preparation); USES (Uses)

```



```

RN 73832-37-8 CAPLUS

CN 4(3H)-Quinazolinone, 6-amino-2-[(diethylamino)methyl]-3-(2-methylphenyl)-
(9CI) (CA INDEX NAME)



L8 ANSWER 50 OF 57 CAPLUS COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 1980:216 CAPLUS
 DOCUMENT NUMBER: 92:216
 TITLE: Monoamine oxidase inhibitory activity of
 4(3H)-quinazolinones of dopamine
 AUTHOR(S): Ahmad, Shakeel; Satsangi, R. K.
 CORPORATE SOURCE: Dep. Pharmacol. Ther., King George's Med. Coll.,
 Lucknow, India
 SOURCE: Indian J. Pharm. Sci. (1979), 41(3), 126-7
 CODEN: IJSIDW
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



I

AB The title compds. I (R = Ph, PhCH:CH, or benzamidomethyl; R1 = H, Br or Cl; R2 = H, Br, Cl, or I) were evaluated for monoamine oxidase [9001-66-5] inhibiting activity in vitro. The dibromo deriv. was more inhibiting than the mono deriv. Structure-activity relations are discussed.


IT 68501-50-8

RL: **BIOL (Biological study)**
 (as monoamine oxidase inhibitor)


RN 68501-50-8 CAPLUS

CN Benzamide, N-[[3-[2-(3,4-dihydroxyphenyl)ethyl]-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)

DOCUMENT NUMBER: 89:135653
 TITLE: Antioxidative stabilization of cosmetic emulsions
 AUTHOR(S): Kokoshvili, E. M.; Sokolova, T. N.; Klyachko, Yu. A.;
 Lyubarskii, L. N.; Skvortsova, A. B.; Chernova, E. M.
 CORPORATE SOURCE: Rizh. Proizvod. Ob'edin. Parfyumerno-Kosmet. Prom.
 "Dzintars", Riga, USSR
 SOURCE: Maslo-Zhir. Prom-st. (1978), (7), 29-30
 CODEN: MZPYAE; ISSN: 0025-4649
 DOCUMENT TYPE: Journal
 LANGUAGE: Russian
 AB Of the 4 antioxidants tested for stabilizing cosmetic emulsions, Antal C
 [67298-14-0] was the best. Antioxidant-property studies at various
 concns. (0.1-1%) at 20.degree. and 40.degree. for 12 mo (peroxide no.
 detn.) indicated that optimum concn. of Antal C was 0.25-0.5%.
 IT 51931-47-6
 RL: BIOL (Biological study)
 (antioxidant, for cosmetic emulsions)
 RN 51931-47-6 CAPLUS
 CN 2-Quinazolinecarboximidamide, 1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



→ L8 ANSWER 53 OF 57 CAPLUS COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 1977:83505 CAPLUS
 DOCUMENT NUMBER: 86:83505
 TITLE: Synthesis and central nervous system activity of
 quinazolones related to 2-methyl-3-(o-tolyl)-4(3H)-
 quinazalone (methaqualone)
 AUTHOR(S): Ager, I. R.; Harrison, D. R.; Kennewell, P. D.;
 Taylor, J. B.
 CORPORATE SOURCE: Roussel Lab., Covingham/Swindon/Wiltshire, Engl.
 SOURCE: J. Med. Chem. (1977), 20(3), 379-86
 CODEN: JMCMAR
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI

I, R=CH₂F, HClII, R=CH₂SC(=NH)NH₂, HBr

AB A series of 71 title compds. was prepd. by condensation of acetylanthranilates with the appropriate arylamines, or by bromination of methaqualone [72-44-6] in the 2-Me group followed by displacement of the Br atom with Cl or F, or N, O, or S nucleophiles. Only the 2-fluoromethyl

deriv. (I) [61555-12-2] or certain isothiuronium salts, e.g., 2-[[3'-(o-tolyl)-4'(3'H)-oxoquinazolin-2'-yl]methylthiuronium bromide (II) [61554-89-0], which could be hydrolyzed in vivo to the 2-mercaptomethyl deriv., [61555-13-3], had central nervous system depressant activity of the same magnitude as methaqualone. Activity of the compds. in mice was detd. by 5 tests, i.e., the loss of righting reflex, rotating drum test, antagonism of convulsions from max. electroshock and pentylenetetrazole, and antagonism of writhing from p-benzoquinone. Structure-activity relations are discussed.


IT 61555-09-7

RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)

(central nervous system depressant activity of)

RN 61555-09-7 CAPLUS


CN 4(3H)-Quinazolinone, 2-[[1,1-dimethylethylamino]methyl]-3-(2-methylphenyl)-; monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L8 ANSWER 54 OF 57 CAPLUS COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 1975:465305 CAPLUS
 DOCUMENT NUMBER: 83:65305
 TITLE: Preservation and analysis of acetomethoxane
 AUTHOR(S): Terekhina, I. A.; Zelenetskaya, A. A.; Deryacheva, L. A.; Skvortsova, A. B.
 CORPORATE SOURCE: Vses. Nauchno-Issled. Inst. Sint. Nat. Dushistykh Veshchestv, Selo Vorontsovo, USSR
 SOURCE: Maslo-Zhir. Promst. (1974), (8), 27-8

RL: **BIOL (Biological study)**
 (stabilizer, for spoilage prevention in cosmetics and perfume)
 RN 51931-47-6 CAPLUS
 CN 2-Quinazolinecarboximidamide, 1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)



→ L8 ANSWER 56 OF 57 CAPLUS COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 1968:442637 CAPLUS
 DOCUMENT NUMBER: 69:42637
 TITLE: Effect of some newer monoamine oxidase inhibitors on catechol amine induced pressor responses
 AUTHOR(S): Gupta, T. K.; Kohli, R. P.; Parmar, Surendra S.; Arora, R. C.
 CORPORATE SOURCE: K. G. Med. Coll., Lucknow Univ., Lucknow, India
 SOURCE: Jap. J. Pharmacol. (1968), 18(2), 169-74
 CODEN: JJPAAZ
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB At doses of 5 mg./kg., 2-ethylhydrazino-3-phenyl-4-quinazalone (QZH-2), 2-methyl-3(2')-benzoylhydrazino-4-quinazalone (QZH-3), and 2-methyl-3(4')-benzoylhydrazino-6-bromo-4-quinazalone (QZH-6) potentiated the epinephrine- and norepinephrine-induced pressor responses in bilaterally vagotomized cats. However, at the same dosage, 2-methylhydrazino-3-phenyl-4-quinazalone (QZH-1), 2-methyl-3-(4')-benzoylhydrazino-4-quinazalone (QZH-4), 2-methyl-3(4')-benzoylhydrazino-6-chloro-4-quinazalone (QZH-5), and 2-methyl 3(4')-benzoylhydrazino-6-iodo-4-quinazalone (QZH-7) did not have such potentiating properties. There was no definite correlation between the potentiation of catechol amine responses by the various monoamine oxidase inhibitors and their in vitro monoamine oxidase-inhibitory activity.
 IT **15647-65-1**
 RL: **BIOL (Biological study)**
 (blood pressure response to pyrocatechol amines and)
 RN 15647-65-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(2-hydrazinoethyl)-3-phenyl- (8CI, 9CI) (CA INDEX NAME)



L8 ANSWER 57 OF 57 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1968:11537 CAPLUS
DOCUMENT NUMBER: 68:11537
TITLE: Anticonvulsant properties of some newer monoamine
oxidase inhibitors
AUTHOR(S): Kohli, R. P.; Gupta, Trihuvan Kumar; Parmar, Surendra
S.; Arora, Ramesh C.
CORPORATE SOURCE: Dep. Pharmacol. Therap, K. G. Med. Coll., Lucknow
Univ., Lucknow, India
SOURCE: Jpn. J. Pharmacol. (1967), 17(3), 409-15
CODEN: JJPAAZ
DOCUMENT TYPE: Journal
LANGUAGE: English

AB In vivo inhibition of monoamine oxidase by quinazoline hydrazides and quinazolinone hydrazines was detd. by the dopa response test and the reserpine reversal test (Chessin, et al., CA 51: 13199f; Everett, et al., CA 60: 8501b). Administration of dopa to animals treated with 1-methylphenpropyl hydrazine (JB-835), pargyline, or phenelzine (all given i.p. at 20 mg./kg.) caused marked stimulation, piloerection, increased motor activity, irritability, tremors, jerks, straub tail, exophthalmus, and fighting behavior. The monoamine oxidase inhibitors, 2-ethylhydrazino-3-phenyl-4-quinazolinone (QZH-2), 2-methyl-3(4')-benzoylhydrazino-6-chloro-4-quinazolinone (QZH-5), or 2-methyl-3(4')-benzoylhydrazino-6-iodo-4-quinazolinone (QZH-7) (oral administration of 150 mg./kg.), produced mild stimulation and a slight increase in motor activity after dopa administration. Oral administration of 2-methyl-3(2')-benzoylhydrazino-4-quinazolinone (QZH-3) or 2-methyl-3(4')-benzoylhydrazino-6-bromo-4-quinazolinone (QZH-6) (both 150 mg./kg.) caused only a slight stimulation without any increase in activity while 2-methylhydrazino-3-phenyl-4-quinazolinone (QZH-1) and 2-methyl-3(4')-benzoylhydrazino-4-quinazolinone (QZH-4) were devoid of any dopa-potentiating effect. I.p. injection of JB-835, pargyline, or phenelzine (all 20 mg./kg.) prior to i.p. administration of 5 mg. reserpine/kg. into mice reversed the effect of reserpine and produced marked excitation, exophthalmus, piloerection, and other sympathomimetic effects. Oral administration of QZH-3, QZH-5, or QZH-7 produced only a partial reversal of the effects of reserpine, causing only a slight stimulation and no marked increase in activity or other sympathomimetic signs. No reversal of the effects of reserpine was observed in animals pretreated with QZH-1, QZH-2, QZH-4, or QZH-6. The protective effect of the monoamine oxidase inhibitors against convulsions induced in rats by s.c. injection of pentylenetetrazole (80 mg./kg.) showed no relation with the in vitro inhibition of monoamine oxidase activity which was reported previously (Parmar and Arora, CA 65: 13701f). QZH-2, QZH-3, QZH-5, QZH-6,

09/ 724,941

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Jan 25 BLAST(R) searching in REGISTRY available in STN on the Web
NEWS 3 Jan 29 FSTA has been reloaded and moves to weekly updates
NEWS 4 Feb 01 DKILIT now produced by FIZ Karlsruhe and has a new update
frequency
NEWS 5 Feb 19 Access via Tymnet and SprintNet Eliminated Effective 3/31/02
NEWS 6 Mar 08 Gene Names now available in BIOSIS
NEWS 7 Mar 22 TOXLIT no longer available
NEWS 8 Mar 22 TRCTHERMO no longer available
NEWS 9 Mar 28 US Provisional Priorities searched with P in CA/CAPLUS
and USPATFULL
NEWS 10 Mar 28 LIPINSKI/CALC added for property searching in REGISTRY
NEWS 11 Apr 02 PAPERCHEM no longer available on STN. Use PAPERCHEM2 instead.
NEWS 12 Apr 08 "Ask CAS" for self-help around the clock
NEWS 13 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 14 Apr 09 ZDB will be removed from STN
NEWS 15 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 16 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 17 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 18 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 19 Jun 03 New e-mail delivery for search results now available
NEWS 20 Jun 10 MEDLINE Reload
NEWS 21 Jun 10 PCTFULL has been reloaded
NEWS 22 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 23 Jul 19 NTIS to be reloaded July 28, 2002

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:36:56 ON 22 JUL 2002

09/ 724,941

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:37:20 ON 22 JUL 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 21 JUL 2002 HIGHEST RN 439659-64-0

DICTIONARY FILE UPDATES: 21 JUL 2002 HIGHEST RN 439659-64-0

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES
for more information. See STNote 27, Searching Properties in the CAS
Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 09724941.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,H,S

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 10:37:37 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 2268 TO ITERATE

44.1% PROCESSED 1000 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 42505 TO 48215

PROJECTED ANSWERS: 35046 TO 40250

09/ 724,941

L2 50 SEA SSS SAM L1

=> s l1 ful
FULL SEARCH INITIATED 10:37:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 44570 TO ITERATE

100.0% PROCESSED 44570 ITERATIONS 36714 ANSWERS
SEARCH TIME: 00.00.10

L3 36714 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 141.42 141.63

FILE 'CAPLUS' ENTERED AT 10:39:42 ON 22 JUL 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Jul 2002 VOL 137 ISS 4
FILE LAST UPDATED: 21 Jul 2002 (20020721/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.


=> s l3
L4 248 L3
=> s l4 and (carbonyl or carboxamid? or sulfon?)
139778 CARBONYL
15839 CARBOXAMID?
229803 SULFON?
L5 21 L4 AND (CARBONYL OR CARBOXAMID? OR SULFON?)

=> d l5 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 21 ANSWERS - CONTINUE? Y/(N):y

L5 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2001:319882 CAPLUS
DOCUMENT NUMBER: 134:326543
TITLE: Methods and compositions utilizing quinazolinones as KSP kinesin modulators
INVENTOR(S): Finer, Jeffrey T.; Bergnes, Gustave; Feng, Bainian; Smith, Whitney W.; Chabala, John C.
PATENT ASSIGNEE(S): Cytokinetics, Inc., USA

SOURCE: PCT Int. Appl., 168 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030768	A1	20010503	WO 2000-US29585	20001026
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 1999-198253P	P 19991027
			US 2000-213104P	P 20000621
OTHER SOURCE(S):		MARPAT 134:326543		
GI				



AB Quinazolinones (I) [wherein R¹ = H, alkyl, (hetero)aryl, or (un)substituted alkyl(hetero)aryl; R² and R^{2a} = independently H or (un)substituted (oxa)alkyl, (hetero)aryl, or alkyl(hetero)aryl; Y = NR⁴COR³, NR⁴SO₂R^{3a}, NR⁴CH₂R^{3b}, or NHR⁴; R³ = H, oxaalkyl, or (un)substituted alkyl, (hetero)aryl, alkyl(hetero)aryl, oxaalkylaryl, ether, or amino; R^{3a} = H or (un)substituted alkyl, (hetero)aryl, alkyl(hetero)aryl, or amino; R^{3b} = (un)substituted alkyl, (hetero)aryl, or alkyl(hetero)aryl; R⁴ = H or (un)substituted alkyl, (hetero)aryl, alkyl(hetero)aryl, or alkylene; R⁵-R⁸ = independently H, (fluoro)alkyl, alkoxy, halo, NO₂, dialkylamino, alkylsulfonyl, alkylsulfonamido(alkyl or aryl), alkylthio, carboxyalkyl, **carboxamido**, aminocarbonyl, or (hetero)aryl] were prepd. by conventional and solid phase combinatorial synthetic methods as KSP kinesin inhibitors for treatment of cellular proliferative diseases. For example, II was synthesized in a 6-step sequence involving (1) amidation of anthranilic acid with butyryl chloride (65%), (2) cyclization to give 2-propyl-3,1-[4H]benzoxazin-4-one (62%), (3) treatment with PhCH₂NH₂ to give 2-propyl-3-benzylquinazolin-4-one (67%), bromination (92%), addn. of N,N-dimethylethylenediamine (55%), and

(6) amidation with p-fluorobenzoyl chloride (65%). I are useful for treating cancer, hyperplasia, restenosis, cardiac hypertrophy, immune disorders, and inflammation (no data). Methods of screening for compds. that will bind to a KSP kinesin or are modulators of KSP kinesin activity are also disclosed.


IT **336119-86-9DP**, resin-bound **336119-90-5P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of quinazolinone KSP kinesin modulators via conventional and solid phase combinatorial synthetic methods)


RN 336119-86-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-[1-[(3-aminopropyl)amino]propyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 336119-90-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[1-[[2-(dimethylamino)ethyl]amino]propyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




IT **336115-13-0P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of quinazolinone KSP kinesin modulators via conventional and solid phase combinatorial synthetic methods)

RN 336115-13-0 CAPLUS

CN Benzamide, N-(3-aminopropyl)-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-methylpropyl]-4-methyl- (9CI) (CA INDEX NAME)



336117-17-0P 336117-19-2P 336117-21-6P
 336117-24-9P 336117-26-1P 336117-28-3P
 336117-30-7P 336117-32-9P 336117-34-1P
 336117-36-3P 336117-38-5P 336117-40-9P
 336117-42-1P 336117-44-3P 336117-46-5P
 336117-48-7P 336117-50-1P 336117-52-3P
 336117-54-5P 336117-56-7P 336117-58-9P
 336117-60-3P 336117-62-5P 336117-65-8P
 336117-67-0P 336117-69-2P 336117-71-6P
 336117-74-9P 336117-76-1P 336117-78-3P
 336117-80-7P 336117-82-9P 336117-84-1P
 336117-86-3P 336117-88-5P 336117-90-9P
 336117-92-1P 336117-94-3P 336117-96-5P
 336117-98-7P 336118-02-6P 336118-04-8P
 336118-06-0P 336118-09-3P 336118-12-8P
 336118-16-2P 336118-18-4P 336118-20-8P
 336118-22-0P 336118-24-2P 336118-27-5P
 336118-30-0P 336118-32-2P 336118-34-4P
 336118-36-6P 336118-39-9P 336118-41-3P
 336118-43-5P 336118-45-7P 336118-47-9P
 336118-49-1P 336118-51-5P 336118-53-7P
 336118-55-9P 336118-57-1P 336118-59-3P
 336118-61-7P 336118-64-0P 336118-66-2P
 336118-68-4P 336118-70-8P 336118-72-0P
 336118-74-2P 336118-76-4P 336118-78-6P
 336118-80-0P 336118-82-2P 336118-85-5P
 336118-88-8P 336118-91-3P 336118-93-5P
 336118-95-7P 336118-97-9P 336118-99-1P
 336119-03-0P 336119-05-2P 336119-07-4P
 336119-11-0P 336119-15-4P 336119-17-6P
 336119-19-8P 336119-21-2P 336119-23-4P
 336119-25-6P 336119-27-8P 336119-29-0P
 336119-31-4P 336119-33-6P 336119-35-8P
 336119-37-0P 336119-39-2P 336119-40-5P
 336119-41-6P 336119-42-7P 336119-43-8P
 336119-44-9P 336119-45-0P 336119-46-1P
 336119-47-2P 336119-48-3P 336119-49-4P
 336119-50-7P 336119-51-8P 336119-52-9P
 336119-53-0P 336119-54-1P 336119-55-2P
 336119-56-3P 336119-57-4P 336119-58-5P
 336119-59-6P 336119-60-9P 336119-61-0P
 336119-62-1P 336119-63-2P 336119-64-3P
 336119-65-4P 336119-66-5P 336119-67-6P
 336119-68-7P 336119-69-8P 336119-70-1P
 336119-71-2P 336119-72-3P 336119-73-4P
 336119-74-5P 336119-75-6P 336119-76-7P
 336119-77-8P 336119-78-9P 336119-79-0P
 336119-80-3P 336119-81-4P 336119-82-5P
 336119-83-6P 336119-84-7P 336119-85-8P
 336125-01-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of quinazolinone KSP kinesin modulators via conventional and solid phase combinatorial synthetic methods)

RN 336116-57-5 CAPLUS



CN Benzamide, 3-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)

09/ 724,941




RN 336116-59-7 CAPLUS

CN 2-Quinolinecarboxamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336116-61-1 CAPLUS

CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 336116-63-3 CAPLUS

CN Benzamide, 3,4-dichloro-N-[1-(7-chloro-3-ethyl-3,4-dihydro-4-oxo-2-quinazolinyl)propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 336119-83-6 CAPLUS

CN 4(3H)-Quinazolinone, 2-[1-[(3-aminopropyl)[(3,5-dimethoxyphenyl)methyl]amino]propyl]-7-chloro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 336119-84-7 CAPLUS

CN Benzoic acid, 4-[[[(3-aminopropyl)[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 336119-85-8 CAPLUS


CN 4(3H)-Quinazolinone, 2-[1-[(3-aminopropyl)[[4-(1,1-dimethylethyl)phenyl]methyl]amino]propyl]-7-chloro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



09/ 724,941

RN 336125-01-0 CAPLUS

CN 1-Naphthalenecarboxamide, N-[1-[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




IT 336119-87-0P 336119-88-1P

RL: PUR (Purification or recovery); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of quinazolinone KSP kinesin modulators via conventional and solid phase combinatorial synthetic methods)


RN 336119-87-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-(1-aminopropyl)-7-chloro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 336119-88-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-(1-amino-2-methylpropyl)-7-chloro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:208250 CAPLUS

DOCUMENT NUMBER: 134:252352

TITLE: Preparation of 3-aryl-2-aryllureidoalkylquinazolin-4-ones and related compounds as mediators of hedgehog

signaling pathways.
 INVENTOR(S): Baxter, Anthony David; Boyd, Edward Andrew; Guichert, Oivin M.; Price, Stephen; Rubin, Lee D.
 PATENT ASSIGNEE(S): Curis, Inc., USA
 SOURCE: PCT Int. Appl., 177 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001019800	A2	20010322	WO 2000-US25461	20000915
WO 2001019800	A3	20011206		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1216234	A2	20020626	EP 2000-963551	20000915
------------	----	----------	----------------	----------

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

PRIORITY APPLN. INFO.:
 US 1999-154526P P 19990916
 US 1999-159412P P 19991014
 US 1999-162899P P 19991101
 WO 2000-US25461 W 20000915

OTHER SOURCE(S): MARPAT 134:252352


AB R1LX1Y1Z1LX2Y2Z2LR2 [R1, R2 = H, alkyl, (substituted) aryl, aralkyl, heteroaryl, heteroarylalkyl; L = null, alkyl, alkenyl, alkynyl, (CH2)nO(CH2)p, etc.; n, p = 0-10; X1, X2 = NR8, O, S, Se, N:N, ON:CH, heterocyclyl, bond, etc.; Y1, Y2 = CO, CS, SO2, SO, C(:NCN), heteroaryl, bond, etc.; Z1, Z2 = NR8, O, S, Se, N:N, ON:CH, heterocyclyl, bond, etc.; R8 = H, alkyl, (substituted) aryl, aralkyl, heteroaryl, heteroaralkyl, etc.], were prepd. Thus, triphosgene in EtOAc was added to 4-nitro-3-trifluoromethylaniline in EtOAc followed by stirring and reflux. The mixt. was concd., dissolved in CHCl3, and treated with 3-(4-fluorophenyl)-2-(1-methylaminoethyl)-4-oxo-3,4-dihydroquinazoline in CHCl3 to give 97% 1-[1-[3-(4-fluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl]ethyl]-3-(3-trifluoromethyl-4-nitrophenyl)-1-methylurea. The latter inhibited sonic hedgehog-induced Gli transcription activity with IC50 <5 .mu.M.

IT 330796-20-8P 330796-21-9P 330796-24-2P
 330796-25-3P 330796-27-5P 330796-28-6P
 330796-29-7P 330796-30-0P 330796-31-1P
 330796-43-5P 330796-44-6P 330796-45-7P
 330796-46-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of 3-aryl-2-arylureidoalkylquinazolin-4-ones and related compds. as mediators of hedgehog signaling pathways)


RN 330796-20-8 CAPLUS

CN Urea, N-[2-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 330796-21-9 CAPLUS

CN Urea, N-[[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 330796-24-2 CAPLUS

CN Urea, N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 330796-25-3 CAPLUS


CN Urea, N-(2,6-dichloro-4-pyridinyl)-N'-[[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]- (9CI) (CA INDEX NAME)



RN 330796-27-5 CAPLUS


CN Urea, N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

09/ 724,941




RN 330796-28-6 CAPLUS

CN Urea, N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N'-[2-methoxy-5-(trifluoromethyl)phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 330796-29-7 CAPLUS

CN Benzamide, N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N-methyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 330796-30-0 CAPLUS

CN Benzenesulfonamide, N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N-methyl-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 330796-31-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-[1-[bis(2-methoxyethyl)amino]ethyl]-3-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 330796-43-5 CAPLUS

CN Urea, N'-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 330796-44-6 CAPLUS

CN Urea, N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N-methyl-N'-[3-[(trifluoromethyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 330796-45-7 CAPLUS

CN Urea, N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N-methyl-N'-[4-(4-methyl-1-piperazinyl)-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 330796-46-8 CAPLUS

CN Urea, N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N-methyl-N'-[4-nitro-3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




IT 330796-47-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of 3-aryl-2-aryluureidoalkylquinazolin-4-ones and related
comps. as mediators of hedgehog signaling pathways)

RN 330796-47-9 CAPLUS

CN Urea, N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N-methyl-N'-(3-nitrophenyl)- (9CI) (CA INDEX NAME)




IT 330796-22-0P 330796-23-1P 330796-26-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)(prepn. of 3-aryl-2-aryluureidoalkylquinazolin-4-ones and related
comps. as mediators of hedgehog signaling pathways)


RN 330796-22-0 CAPLUS

CN Carbamic acid, [[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 330796-23-1 CAPLUS

CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



09/ 724,941

RN 330796-26-4 CAPLUS
CN 4(3H)-Quinazolinone, 3-(4-fluorophenyl)-2-[1-(methylamino)ethyl]- (9CI)
(CA INDEX NAME)



L5 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:91539 CAPLUS

DOCUMENT NUMBER: 134:147610

TITLE: Compositions containing N-amino- and N-hydroxy-quinazolinones and methods for preparing combinatorial libraries thereof

INVENTOR(S): Gao, Yun

PATENT ASSIGNEE(S): Sepracor Inc., USA

SOURCE: U.S., 15 pp.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6184377	B1	20010206	US 1997-990855	19971215
US 2001018518	A1	20010830	US 2001-775339	20010201

PRIORITY APPLN. INFO.: US 1997-990855 A1 19971215

OTHER SOURCE(S): MARPAT 134:147610


GI




AB The invention is directed to certain N-amino- and N-hydroxy-quinazolinone compds., and methods for their synthesis. The compds. may find use in combinatorial libraries. More specifically, the invention is directed to the synthesis of 3-hydroxy- and 3-amino-4(1H)-quinazolinones via the reaction of an appropriate 2-aminobenzamide compd. with a carboxylic acid or acyl halide at ambient temp., performed on a solid support or in soln. In particular, the compds. are prepd. via supported compds. I [R1 = H, halo, alkyl, OH, alkoxy, etc.; or adjacent (R1)2 = (hetero)arom. fusion; R2 = (un)substituted alkyl, alkoxy, N-protected amino acid residue, Ph, etc.; Z = NHCO2CH2-Sup, OCH2-Sup, etc.; Sup = solid support]. For instance, Sup-ONH2 reacted with 15 isatoic anhydrides to give 15 supported

2-amino-N-hydroxybenzamides Sup-ONH-CO-C₆H₄-n(R₁)n-NH₂-2. The latter compds. were mixed into 5 groups of 3, and each group was then split 16 ways and cyclized sep. with each of 16 Fmoc-protected amino acids, using PyBrOP in DMAC as the condensing agent. Each of the 80 resultant Fmoc-protected quinazolinone mixts. was deprotected with piperidine, sepd. into 24 wells of a reactor block, and reacted with a selection of 8 chloroformates, 8 **sulfonyl** chlorides, and 8 isocyanates. The resulting 1920 product mixts. were treated with TFA to cleave the resin, yielding a library of 5760 different 3-hydroxyquinazolin-4-ones [II; R₁ = H, Me, MeO, halo, and/or NO₂; R₂ = amino acid sidechain; R₃ = other sidechain forming a carbamate, **sulfonamide**, or urea group], as 3-compd. mixts., which were stored for future bioassay.

IT **324528-85-0DP**, derivs., resin-bound **324528-86-1DP**, resin-bound
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; methods for prepn. of N-amino- and N-hydroxy-quinazolinones and combinatorial libraries thereof)
 RN 324528-85-0 CAPLUS
 CN Carbamic acid, [(3,4-dihydro-3-hydroxy-4-oxo-2-quinazolinyl)methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)




RN 324528-86-1 CAPLUS
 CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-hydroxy- (9CI) (CA INDEX NAME)



IT **324528-53-2P 324528-54-3P 324528-55-4P 324528-61-2P 324528-62-3P 324528-88-3DP**, esters, derivs. **324528-91-8DP**, derivs. **324528-92-9DP**, derivs. **324528-94-1DP**, derivs.
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (target compd.; methods for prepn. of N-amino- and N-hydroxy-quinazolinones and combinatorial libraries thereof)
 RN 324528-53-2 CAPLUS
 CN Benzenesulfonamide, 4-bromo-N-[(1S)-1-(3,4-dihydro-3-hydroxy-4-oxo-2-quinazolinyl)-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 724,941



RN 324528-54-3 CAPLUS

CN Carbamic acid, [(1S)-1-(3,4-dihydro-3-hydroxy-4-oxo-2-quinazolinyl)-2-phenylethyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 324528-55-4 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(1S)-1-(3,4-dihydro-3-hydroxy-6-nitro-4-oxo-2-quinazolinyl)-2-methylpropyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 324528-61-2 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-2-[(1S)-1-amino-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 724,941



RN 324528-62-3 CAPLUS


CN 4(3H)-Quinazolinone, 3-amino-2-[(1S)-1-amino-2-phenylethyl]-6-chloro-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 324528-88-3 CAPLUS

CN Carbamic acid, [(3,4-dihydro-3-hydroxy-4-oxo-2-quinazolinyl)methyl]- (9CI)
(CA INDEX NAME)




RN 324528-91-8 CAPLUS

CN Urea, [(3,4-dihydro-3-hydroxy-4-oxo-2-quinazolinyl)methyl]- (9CI) (CA
INDEX NAME)




RN 324528-92-9 CAPLUS

CN Methanesulfonamide, N-[(3,4-dihydro-3-hydroxy-4-oxo-2-quinazolinyl)methyl]-
(9CI) (CA INDEX NAME)



RN 324528-94-1 CAPLUS

CN Benzenesulfonamide, N-[(3,4-dihydro-3-hydroxy-4-oxo-2-quinazolinyl)methyl]-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:666928 CAPLUS

DOCUMENT NUMBER: 133:261508

TITLE: Screening of antiviral compounds targeted to the HIV-1 gp41 core structure

INVENTOR(S): Jiang, Shibo; Debnath, Asim K.

PATENT ASSIGNEE(S): New York Blood Center, Inc., USA

SOURCE: PCT Int. Appl., 79 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000055377	A1	20000921	WO 2000-US6771	20000315
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1161564	A1	20011212	EP 2000-917952	20000315
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.:

US 1999-124907P P 19990317

US 2000-525874 A 20000314

WO 2000-US6771 W 20000315

OTHER SOURCE(S): MARPAT 133:261508

AB A method for the screening of antiviral compds. targeted to the HIV-1 gp41

core structure comprises capturing polyclonal antibodies from an animal other than a mouse directed against a trimer of a heterodimer contg. an N-peptide and a C-peptide onto a solid-phase, mixing a compd. to be tested with an N-peptide and then adding a C-peptide, adding the resultant mixt. to the resultant polyclonal antibody-coated solid-phase and then removing unbound peptides and unbound compd., adding a monoclonal antibody directed against the trimer of a heterodimer contg. an N-peptide and a C-peptide and measuring the antibody binding of the monoclonal antibody. A method for inhibiting HIV-1 virus replication or infectivity in a patient involves administering to the patient an antiviral compd. targeted to the HIV-1 gp41 core structure selected from the group consisting of 7-[6-phenylamino-4-[4-[(3,5-disulfo-8-hydroxynaphthyl)azo]-2-methoxy-5-methyl-phenylamino]-1,3,5-triazine-2-yl]-4-hydroxy-3-[(2-methoxy-5-sulfo-phenyl)azo]-2-naphthalene **sulfonic acid** and 5-[(4-chloro-6-phenylamino-1,3,5-triazine-2-yl)-aminol]-4-hydroxy-3-[(4-methyl-5-sulfo-phenyl)azo]-2,7-naphthalene disulfonic acid.

IT 245764-86-7 245764-87-8 245764-88-9



245764-89-0 245764-90-3 294844-30-7

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(screening of antiviral compds. targeted to HIV-1 gp41 core structure)


RN 245764-86-7 CAPLUS

CN Urea, N-[1-(1,4-dihydro-4-oxo-2-quinazolinyl)ethyl]-N-(2,4-dimethylphenyl)-N'-phenyl- (9CI) (CA INDEX NAME)



RN 245764-87-8 CAPLUS


CN Urea, N'-(3-chlorophenyl)-N-[1-(1,4-dihydro-4-oxo-2-quinazolinyl)ethyl]-N-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)



09/ 724,941


RN 245764-88-9 CAPLUS

CN Urea, N'-(3,4-dichlorophenyl)-N-[1-(1,4-dihydro-4-oxo-2-quinazolinyl)ethyl]-N-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)




RN 245764-89-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-[1-[(2-chlorophenyl)amino]ethyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 245764-90-3 CAPLUS

CN 1,3-Benzenedicarboxylic acid, 5-[[[(3,4-dichlorophenyl)amino]carbonyl][1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]amino]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 294844-30-7 CAPLUS

CN Benzamide, N-[1-[6-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-N-(4-fluorophenyl)-4-nitro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:561006 CAPLUS

DOCUMENT NUMBER: 133:170210

TITLE: Silver halide photographic material containing dye dispersant and coupler

INVENTOR(S): Iwagaki, Masaru; Kawabe, Satomi; Kawashima, Yasuhiko

PATENT ASSIGNEE(S): Konica Co., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 66 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000227645	A2	20000815	JP 1999-28588	19990205

OTHER SOURCE(S): MARPAT 133:170210

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title photog. material, possessing photog. constitutive layers including .gtoreq.1 blue-photosensitive, .gtoreq.1 green-photosensitive, and .gtoreq.1 red-photosensitive layers and .gtoreq.1 non-photosensitive layer on a support, contains .gtoreq.1 dye I [A = acidic nucleus; L1-3 = methine; n1 = 0-2; X1 = O, S, Se; R11-12 = H, (substituted) alkyl; R13-14 = alkyl], and (i) magenta coupler II (R21 = arylthio; R22 = aryl; R23 = substituent; n2 = 1-5), (ii) .gtoreq.1 cyan coupler III (R31 = alkyl, cycloalkyl; R32 = substituent; n3 = 1-4; X3 = group releasing upon reaction with an oxidized color developing agent) or (iii) .gtoreq.1 DIR compd. IV, V, YTSCR41R42CO2CR46R47X6 or YTSCR41R42CO2(CH2)2W [Y = yellow coupler residue capable of coupling with an oxidized color developing agent; T = (substituted) 1,2,4- or 1,2,3-triazole skeleton linking to the coupling position of Y by N atom; S = S linking to the C atom of T; R41, R46 = H, (substituted) alkyl, (substituted) aryl; R42, R43, R47 = (substituted) alkyl, (substituted) aryl; R44, R45 = substituent; X6 = oxycarbonyl, carbamoyl, **carbonyl**; W = (substituted) aryloxy, (substituted) arylthio, (substituted) **sulfonyl**; n4 = 0-4; m = 0-5]. The material may contain, in .gtoreq.1 of the photog. constitutive layers, a mixt. of .gtoreq.2 dyes in which .gtoreq.80% of the chem. structural formulas are the same but the other structural portions are

09/ 724,941


different from each other. The photog. material shows improved sharpness and storage stability.

IT 287980-01-2

RL: DEV (Device component use); USES (Uses)
(photog. film contg. dye dispersant and coupler)

RN 287980-01-2 CAPLUS

CN Benzoic acid, 4-[2-[2-[[1-[2-[[2-(2-cyclohexylphenoxy)phenyl]amino]-1-(1,4-dihydro-4-oxo-2-quinazolinyl)-2-oxoethyl]-1H-1,2,3-triazol-5-yl]thio]-1-oxopropoxy]ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:189042 CAPLUS

DOCUMENT NUMBER: 130:289163

TITLE: Silver halide color photographic material with improved sharpness and storage stability

INVENTOR(S): Ishige, Osamu; Tozai, Masakazu; Nishizeki, Masato; Sato, Naoki

PATENT ASSIGNEE(S): Konica Co., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 39 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 11072887	A2	19990316	JP 1998-171337	19980618
US 6027867	A	20000222	US 1998-100722	19980619
PRIORITY APPLN. INFO.:			JP 1997-168844	19970625
OTHER SOURCE(S):		MARPAT 130:289163		

GI



AB The Ag halide color photog. material contains a photog. DIR (development inhibitor releasing) coupler represented by I (Y = yellow coupler residue; T = 1,2,4-triazole, 1,2,3-triazole; R1 = H, alkyl, aryl; R2 = alkyl, aryl; R3 = alkyl, aryl; R4 = substituent; n = 0-4), II (Y, T, R1, R2 = same as the above; R5 = alkyl, aryl; m = 0-5), YTSCR1R2COOCR6R7X (Y, T, R1, R2 = same as the above; R6 = H, alkyl, aryl; R7 = alkyl, aryl; X = oxycarbonyl, carbamoyl, **carbonyl**), or YTSCR1R2COOCH2CH2W (Y, T, R1, R2 = same as the above; W = aryloxy, arylthio, **sulfonyl**).

IT 221633-12-1 221633-14-3 221633-32-5
221633-38-1

RL: DEV (Device component use); USES (Uses)

(DIR coupler in silver halide color photog. material with improved sharpness and storage stability)

RN 221633-12-1 CAPLUS

CN Propanoic acid, 2-[[N-[2-[[3-[[[2-(2-cyclohexylphenoxy)phenyl]amino]carbonyl]phenyl]amino]-1-(1,4-dihydro-4-oxo-2-quinazolinyl)-2-oxoethyl]-1H(or 2H)-1,2,3-triazolyl]thio]-, 2,6-dimethylphenyl ester (9CI) (CA INDEX NAME)



CM 1

CRN 221633-11-0

CMF C48 H49 N7 O6 S

CCI IDS

CDES *





RN 221633-14-3 CAPLUS

CN Propanoic acid, 2-[[N-[2-[[3-[[[2-(2-cyclohexylphenoxy)phenyl]amino]carbonyl]phenyl]amino]-1-(1,4-dihydro-4-oxo-2-quinazolinyl)-2-oxoethyl]-1H(or 2H)-1,2,3-triazolyl]thio]-, 2-(1,1-dimethylethyl)phenyl ester (9CI) (CA INDEX NAME)

CM 1

09/ 724,941



CRN 221633-13-2
CMF C50 H53 N7 O6 S
CCI IDS
CDES *



RN 221633-32-5 CAPLUS
CN Propanoic acid, 2-[[N-[2-[[2-(2-cyclohexylphenoxy)phenyl]amino]-1-(1,4-dihydro-4-oxo-2-quinazolinyl)-2-oxoethyl]-1H(or 2H)-1,2,3-triazolyl]thio]-2-(hexyloxy)-1-methyl-2-oxoethyl ester (9CI) (CA INDEX NAME)

CM 1

CRN 221633-31-4
CMF C42 H52 N6 O7 S
CCI IDS
CDES *





09/ 724,941

RN 221633-38-1 CAPLUS
CN Benzoic acid, 4-[2-[2-[[1(or 4)-[2-[[2-(2-cyclohexylphenoxy)phenyl]amino]-1-(1,4-dihydro-4-oxo-2-quinazolinyl)-2-oxoethyl]-1H(or 4H)-1,2,4-triazolyl]thio]-1-oxopropoxy]ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)

CM 1

CRN 221633-37-0
CMF C44 H48 N6 O8 S
CCI IDS
CDES *





IT **221633-02-9P**
RL: DEV (Device component use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)
(in prepn. of photog. DIR coupler)

RN 221633-02-9 CAPLUS
CN Benzoic acid, 4-[2-[2-[[1(or 2)-[2-[[2-(2-cyclohexylphenoxy)phenyl]amino]-1-(1,4-dihydro-4-oxo-2-quinazolinyl)-2-oxoethyl]-1H(or 2H)-1,2,3-triazolyl]thio]-1-oxopropoxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

CM 1


CRN 221633-01-8
CMF C43 H46 N6 O7 S
CCI IDS
CDES *



IT 134555-29-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(in prepn. of photog. DIR coupler)

RN 134555-29-6 CAPLUS

CN 2-Quinazolineacetamide, .alpha.-bromo-N-[2-(2-cyclohexylphenoxy)phenyl]-
1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:89943 CAPLUS

DOCUMENT NUMBER: 130:223234

TITLE: Synthesis and anti-monoamine oxidase activity of
1-(4-quinazolinone-2-carbonyl)-2-alkyl(or
aralkyl)hydrazines

AUTHOR(S): Mekuskiene, G.; Rocka, V.; Vainilavicius, P.

CORPORATE SOURCE: Vil'nyuss. Univ., Vilnius, Lithuania

SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1998), 32(10),
10-12


CODEN: KHFZAN; ISSN: 0023-1134

PUBLISHER: Izdatel'stvo Folium

DOCUMENT TYPE: Journal

LANGUAGE: Russian

GI




AB Title compds. I (R = CHMe₂, CHMePh, CHMeC₆H₄OH-2) were prepd. by condensation of I (R = H) with ketones, followed by borohydride redn. These compds. and the previously prepd. I (R = CH₂Ph, CH₂C₆H₄OH-2) were tested for in vitro anti-monoamine oxidase activity; I (R = CHMe₂, CHMePh) were also tested in vivo. Comparison with previously tested pyrimidine analogs showed that replacement of the pyrimidine moiety by the quinazoline moiety resulted in lower anti-monoamine oxidase activity and lower toxicity.

IT 202746-94-9 221071-86-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(anti-monoamine oxidase activity of)


RN 202746-94-9 CAPLUS

CN 2-Quinazolinecarboxylic acid, 1,4-dihydro-4-oxo-, 2-[(2-hydroxyphenyl)methyl]hydrazide (9CI) (CA INDEX NAME)



RN 221071-86-9 CAPLUS

CN 2-Quinazolinecarboxylic acid, 1,4-dihydro-4-oxo-, 2-(phenylmethyl)hydrazide (9CI) (CA INDEX NAME)




IT 34632-71-8

RL: RCT (Reactant); RACT (Reactant or reagent)
(condensation with ketones)

RN 34632-71-8 CAPLUS

CN 2-Quinazolinecarboxylic acid, 1,4-dihydro-4-oxo-, hydrazide (9CI) (CA INDEX NAME)




IT 221071-87-0P 221071-88-1P 221071-89-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and anti-monoamine oxidase activity of)


RN 221071-87-0 CAPLUS

CN 2-Quinazolinecarboxylic acid, 1,4-dihydro-4-oxo-, 2-(1-methylethyl)hydrazide (9CI) (CA INDEX NAME)




RN 221071-88-1 CAPLUS

CN 2-Quinazolinecarboxylic acid, 1,4-dihydro-4-oxo-, 2-(1-phenylethyl)hydrazide (9CI) (CA INDEX NAME)



RN 221071-89-2 CAPLUS

CN 2-Quinazolinecarboxylic acid, 1,4-dihydro-4-oxo-, 2-[1-(2-hydroxyphenyl)ethyl]hydrazide (9CI) (CA INDEX NAME)



IT 202746-92-7P 202747-09-9P 221071-85-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

09/ 724,941

(prepn. and redn. of)


RN 202746-92-7 CAPLUS

CN 2-Quinazolinecarboxylic acid, 1,4-dihydro-4-oxo-, [1-(2-hydroxyphenyl)ethylidene]hydrazide (9CI) (CA INDEX NAME)




RN 202747-09-9 CAPLUS

CN 2-Quinazolinecarboxylic acid, 1,4-dihydro-4-oxo-, (1-phenylethylidene)hydrazide (9CI) (CA INDEX NAME)



RN 221071-85-8 CAPLUS

CN 2-Quinazolinecarboxylic acid, 1,4-dihydro-4-oxo-, (1-methylethylidene)hydrazide (9CI) (CA INDEX NAME)



L5 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1999:19452 CAPLUS

DOCUMENT NUMBER: 130:177140

TITLE: Correspondence analysis of protein kinase C (PKC) inhibition by bis-basic substituted benzamides

AUTHOR(S): Gilbert, Jacques; Cheminant, Michel; Bignon, Eric; Pons, Michel; Ojasoo, Tiiu; Dore, Jean-Christophe

CORPORATE SOURCE: CNRS-SIRCOB, Universite de Versailles/St. Quentin-en-Yvelines, Versailles, 78000, Fr.

SOURCE: Drug Design and Discovery (1998), 15(4), 253-267, 2 plates

CODEN: DDDIEV; ISSN: 1055-9612

PUBLISHER: Harwood Academic Publishers

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The synthesis of a novel series of bis-basic substituted benzamides and their relative potency in inhibiting rat brain protein kinase alpha

(PKC.alpha.) activity were described. None of the compds. inhibited enzyme activity via the catalytic domain but several did via the regulatory domain at 1-5.mu.M concns. Inhibition was comparable to that of several di- and triphenylacrylonitriles and triphenylethylenes. According to a multivariate factor (correspondence) anal. of QSAR descriptors, hydrophobicity (log p) and hydration energy were the most discriminant descriptors, much more so than mol. mass, molar refractivity, polarizability, mol. vol. and solvent-accessible surface. Inhibitory activity was correlated with high hydrophobicity and low hydration energy. The higher potency of N,N'-oxalylbis[(o-amino) [2-(diethylamino)ethyl]benzamide] (GL9) that differed from its congener by the presence of an oxamide rather than succinamide moiety was tentatively explained by the greater neg. charges assocd. with the **carbonyl** groups of its oxamide residue. The higher potency of N,N'-terephthalylbis[(o-amino) [2-(diethylamino)ethyl]benzamide] (GL22) in which an arom. ring is inserted between two benzamide moieties in para,para' rather than ortho,ortho' positions might be due to a planar conformation facilitating membrane insertion. In conclusion, correspondence anal. is a neat way of highlighting similarities and differences in mol. properties (QSAR descriptors and potency). Therapeutic doses of many classes of drug might interfere with the regulatory domain of PKC.alpha. if, like the test-compds., they have basic side-chain(s), high hydrophobicity, low hydration energy, a planar conformation and/or a highly charged reactive (oxamide) moiety. The compds. thus prepd. were tested against tamoxifen and analogs thereof.


IT 220583-05-1P 220583-08-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. and protein kinase C-inhibiting activity of benzamide derivs.)


RN 220583-05-1 CAPLUS

CN 2-Quinazolinecarboxamide, 3-[2-(diethylamino)ethyl]-3,4-dihydro-4-oxo-
(9CI) (CA INDEX NAME)



RN 220583-08-4 CAPLUS

CN 4(3H)-Quinazolinone, 2,3-bis[2-(diethylamino)ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:422519 CAPLUS


DOCUMENT NUMBER: 125:104245
 TITLE: Potent thrombin inhibitors that probe the S1' subsite: tripeptide transition state analogs based on a heterocycle-activated **carbonyl** group
 AUTHOR(S): Costanzo, Michael J.; Maryanoff, Bruce; Hecker, Leonard R.; Schott, Mary R.; Yabut, Stephen C.; Zhang, Han-Cheng; Andrade-Gordon, Patricia; Kauffman, Jack A.; Lewis, Joan M.; et al.
 CORPORATE SOURCE: R. W. Johnson Pharmaceutical Research Institute, Spring House, PA, 19477, USA
 SOURCE: J. Med. Chem. (1996), 39(16), 3039-3043
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB A series of peptidoyl heterocycles with the motif Me-(D-Phe)-Pro-Arg-Het was synthesized and evaluated for inhibition of human .alpha.-thrombin and bovine trypsin. The preferred form of "Het" was a 2-azole, with the best thrombin inhibitor (K_i = 0.19 nM) having a 2-benzothiazole group (2, RWJ-50353). The best selectivity for thrombin over trypsin (try/thr ratio = 88) was obtained with the N-methyl-2-imidazole group (thrombin K_i = 50 nM). In analogs of 2 with the activated **carbonyl** reduced to an alc. group (two diastereomers), there was a substantial loss of thrombin inhibition, as expected for a transition state analog. Inhibitor 2 shows excellent selectivity for thrombin over other blood coagulation enzymes, such as plasmin (ratio = 12,000), tPA (ratio = 3,300), activated protein C (ratio = 19,000), and streptokinase (ratio = 6,300), but the selectivity of 2 for thrombin over trypsin is more modest (ratio = 16). Compd. 2 has an IC₅₀ value of 23.+-0.2 nM for inhibition of thrombin-induced platelet aggregation (human, gel-filtered). The mol. structure of a complex between 2, human .alpha.-thrombin, and hirugen was detd. by x-ray crystallog. Besides the std. active-site interactions for tripeptide thrombin inhibitors, the structure shows novel interactions in the S1' region, where the benzothiazole ring forms a hydrogen bond with His-57 and an arom. stacking interaction with Trp-60D of the unique insertion loop of thrombin.

IT 178926-01-7P
 RL: BAC (Biological activity or effector, except adverse); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of peptidoyl heterocycles as potent thrombin inhibitors)

RN 178926-01-7 CAPLUS
 CN L-Prolinamide, N-methyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)amino]-1-[(1,4-dihydro-4-oxo-2-quinazolinyl)carbonyl]butyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:392102 CAPLUS
 DOCUMENT NUMBER: 125:143319
 TITLE: Peptidyl heterocycles useful in the treatment of thrombin related disorders
 INVENTOR(S): Costanzo, Michael J.; Maryanoff, Bruce E.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S., 59 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5523308	A	19960604	US 1995-486473	19950607
CA 2224110	AA	19961219	CA 1996-2224110	19960603
WO 9640748	A1	19961219	WO 1996-US8456	19960603
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
AU 9659713	A1	19961230	AU 1996-59713	19960603
AU 721079	B2	20000622		
EP 833839	A1	19980408	EP 1996-917014	19960603
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI				
CN 1192747	A	19980909	CN 1996-196103	19960603
JP 11506762	T2	19990615	JP 1996-501056	19960603
ZA 9604759	A	19971208	ZA 1996-4759	19960606
NO 9705747	A	19980203	NO 1997-5747	19971205
PRIORITY APPLN. INFO.:			US 1995-486473	A 19950607
			WO 1996-US8456	W 19960603

OTHER SOURCE(S): MARPAT 125:143319

AB Peptidyl heterocycles ANHCR1R2CO[B(CH₂)_nCO]pE (A = alkyl, substituted phenylalkyl, amino acid moiety, etc.; R1 = H, alkyl; R2 = aminoalkyl, alkoxyalkyl, Ph or substituted phenyl; B = 1,2-piperidinediyl or 4-alkyl-1,2-piperidinediyl, n = 0-3; p = 0, 1; E = heterocyclyl) or their pharmaceutically acceptable salts were prepd. for use in the treatment of thrombin and trypsin related disorders. Thus, N-methyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)amino]-1S-[(benzothiazol-2-yl)carbonyl]butyl]-L-prolinamide (1) was prepd. from N-CBZ-N-methyl-D-phenylalanyl-L-prolyl-NG-CBZ-L-arginine-aldehyde by sequential reaction with acetone cyanohydrin, gaseous HCl in MeOH, 2-aminothiophenol, and Dess-Martin periodinane. Compd. 1 and 56 other synthesized compds. were tested for their ability to inhibit thrombin or trypsin mediated hydrolysis. Thr IC₅₀ (.mu.M) and Trp IC₅₀ (.mu.M) values for compd. 1 are 0.00023 and 0.0031, resp.

IT 180059-94-3P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. of peptidyl heterocycles useful in the treatment of thrombin related disorders)


RN 180059-94-3 CAPLUS

CN L-Prolinamide, N-methyl-D-phenylalanyl-N-[4-[(aminoiminomethyl)amino]-1-[(1,4-dihydro-4-oxo-2-quinazolinyl)carbonyl]butyl]-, (S)-, acetate (5:13) (9CI) (CA INDEX NAME)

09/ 724,941


CRN 178926-01-7
CMF C29 H36 N8 O4
CDES *

Absolute stereochemistry.



CM 2

CRN 64-19-7
CMF C2 H4 O2



L5 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1995:346688 CAPLUS

DOCUMENT NUMBER: 122:160664

TITLE: Quinazoline derivatives as neoplasm inhibitors

INVENTOR(S): Barker, Andrew John; Boyle, Francis Thomas; Hennequin, Laurent Francois Andre

PATENT ASSIGNEE(S): Zeneca Ltd., UK; British Technology Group Ltd.

SOURCE: Brit. UK Pat. Appl., 71 pp.

CODEN: BAXXDU

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2271111	A1	19940406	GB 1993-20077	19930929
ZA 9306768	A	19940330	ZA 1993-6768	19930914
WO 9407869	A1	19940414	WO 1993-GB2015	19930928



W: AU, BG, BR, CA, CZ, FI, HU, JP, KR, NO, NZ, PL, PT, RO, RU, SE, SK, UA, US

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.: GB 1992-20571 19920930

OTHER SOURCE(S): MARPAT 122:160664

GI




AB Quinazolines I (R_1 = H, substituent; R_2 = H, alkyl, etc.; A = phenylene, arom. heterocyclene ring; R = Ph, heteroaryl; Q = nitro, cyano, carbamoyl, etc.) were disclosed. Compds. I are useful as antitumor agents. A specifically claimed example compd. is 4-[[[(2-methyl-4-oxo-3,4-dihydro-6-quinazolinyl)methyl](2-propenyl)amino]-.alpha.-(methylsulfonyl)desoxybenzoin (II).

IT 161417-83-0P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of, as neoplasm inhibitor)

RN 161417-83-0 CAPLUS

CN Piperidine, 1-[[[2-[4-[[[2-[(dimethylamino)methyl]-1,4-dihydro-7-methyl-4-oxo-6-quinazolinyl)methyl]-2-propynylamino]-2-fluorophenyl]-1-(4-fluorophenyl)-2-oxoethyl]sulfonyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 12 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1994:457466 CAPLUS

DOCUMENT NUMBER: 121:57466

TITLE: Syntheses of indolyl-4(3H)-quinazolinones

AUTHOR(S): Hermecz, Istvan; Kokosi, Jozsef; Podanyi, Benjamin; Szasz, Gyorgy

CORPORATE SOURCE: CHINOIN Pharm. and Chem. Works Ltd., Budapest, H-1325, Hung.


SOURCE: Heterocycles (1994), 37(2), 903-14

CODEN: HTCYAM; ISSN: 0385-5414

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I


AB 2-(1H-Indol-2-yl)-4(3H)-quinazolinones I (R = H, Me) and 2-(2-ethoxy-carbonyl-1H-indol-3-yl)-4(3H)-quinazolin-4-one were prepd. by the Fischer indolization of 2-(1-phenylhydrazonoalkyl)- and 2-(2-phenylhydrazono-2-ethoxycarbonylethyl)-4(3H)-quinazolinones, resp. Also prepd. was 2-(1H-indol-3-yl)-4(3H)-quinazolinone. A reaction mechanism is discussed.

IT 155912-20-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 155912-20-2 CAPLUS

CN 4(1H)-Quinazolinone, 2-[1-(methylphenylamino)ethyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1993:449324 CAPLUS

DOCUMENT NUMBER: 119:49324

TITLE: 4-(3H)-quinazolones. Part III: Alkyl or arylaminomethyl/substituted cinnamyl-3-p **sulfonamidophenyl**-4-(3H)-quinazolones

AUTHOR(S): Gaur, V. B.; Shah, V. H.; Parikh, A. R.

CORPORATE SOURCE: Chem. Dep., Saurashtra Univ., Rajkot, 360 005, India


SOURCE: J. Inst. Chem. (India) (1991), 63(6), 219-20

CODEN: JOICA7; ISSN: 0020-3254


DOCUMENT TYPE: Journal

LANGUAGE: English


GI



I



II



III



AB Title compds, including aminomethyl derivs. I (R = Ph, 2-MeC6H4, 3-MeC6H4, 4-MeC6H4, 2-MeOC6H4, 3-MeOC6H4, 4-MeOC6H4, 2-O2NC6H4, 3-O2NC6H4, 4-O2NC6H4, 2-ClC6H4, 3-ClC6H4, 4-ClC6H4, 4-BrC6H4, PhCH2, 1-naphthyl, Me, Bu, octadecyl) and styryl derivs. II (R1 = 2-O2NC6H4, 3-O2NC6H4, 4-O2NC6H4, 2-ClC6H4, 3-ClC6H4, 4-ClC6H4), were prepd. from aminosulfonylphenylmethylquinazolinone III. Several aminomethyl derivs., e.g., I (2-O2NC6H4, 3-O2NC6H4, 4-O2NC6H4, 2-ClC6H4, 3-ClC6H4, 4-ClC6H4, Bu, octadecyl) showed good bactericidal and fungicidal activity.

IT 147766-66-3P 147766-67-4P 147766-68-5P
 147766-69-6P 147766-70-9P 147766-71-0P
 147766-72-1P 147766-73-2P 147766-74-3P
 147766-75-4P 147766-76-5P 147766-77-6P
 147766-78-7P 147766-79-8P 147766-80-1P
 147766-81-2P 147766-82-3P 147766-83-4P
 147766-84-5P 147766-85-6P 147766-86-7P
 147792-99-2P 148472-79-1P 148472-80-4P
 149411-85-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)

RN 147766-66-3 CAPLUS


CN Benzenesulfonamide, 4-[2-[[[(2-methylphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 147766-67-4 CAPLUS


CN Benzenesulfonamide, 4-[2-[[[(3-methylphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

09/ 724,941




RN 147766-68-5 CAPLUS

CN Benzenesulfonamide, 4-[2-[[2-methoxyphenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 147766-69-6 CAPLUS

CN Benzenesulfonamide, 4-[2-[[3-methoxyphenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 147766-70-9 CAPLUS


CN Benzenesulfonamide, 4-[2-[[4-methoxyphenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)



09/ 724,941


RN 147766-71-0 CAPLUS

CN Benzenesulfonamide, 4-[2-[[[3-nitrophenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 147766-72-1 CAPLUS

CN Benzenesulfonamide, 4-[2-[[[4-nitrophenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 147766-73-2 CAPLUS

CN Benzenesulfonamide, 4-[2-[[[3-chlorophenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 147766-74-3 CAPLUS

CN Benzenesulfonamide, 4-[2-[[[4-chlorophenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)




RN 147766-75-4 CAPLUS

CN Benzenesulfonamide, 4-[4-oxo-2-[[[(phenylmethyl)amino]methyl]-3(4H)-quinazolinyl]-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 147766-76-5 CAPLUS


CN Benzenesulfonamide, 4-[2-[[[(4-bromophenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl]-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 147766-77-6 CAPLUS


CN Benzenesulfonamide, 4-[2-[[[(1-naphthalenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl]-1-yl]phenyl]- (9CI) (CA INDEX NAME)

09/ 724,941




RN 147766-78-7 CAPLUS

CN Benzoic acid, 4-[[[3-[4-(aminosulfonyl)phenyl]-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 147766-79-8 CAPLUS


CN Benzoic acid, 4-[[[3-[4-(aminosulfonyl)phenyl]-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 147766-80-1 CAPLUS


CN Benzenesulfonamide, 4-[2-[[[2-(hydroxyphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

09/ 724,941




RN 147766-81-2 CAPLUS

CN Benzenesulfonamide, 4-[2-[[[3-hydroxyphenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 147766-82-3 CAPLUS


CN Benzenesulfonamide, 4-[2-[[[4-hydroxyphenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)



RN 147766-83-4 CAPLUS


CN Benzenesulfonamide, 4-[2-[[[cyclohexylamino]methyl]-4-oxo-3(4H)-quinazolinyl]- (9CI) (CA INDEX NAME)

09/ 724,941




RN 147766-84-5 CAPLUS

CN Benzenesulfonamide, 4-[2-[(methylamino)methyl]-4-oxo-3(4H)-quinazolinyl]-
(9CI) (CA INDEX NAME)




RN 147766-85-6 CAPLUS

CN Benzenesulfonamide, 4-[2-[(butylamino)methyl]-4-oxo-3(4H)-quinazolinyl]-
(9CI) (CA INDEX NAME)



RN 147766-86-7 CAPLUS


CN Benzenesulfonamide, 4-[2-[(octylamino)methyl]-4-oxo-3(4H)-quinazolinyl]-
(9CI) (CA INDEX NAME)



RN 147792-99-2 CAPLUS


CN Benzenesulfonamide, 4-[2-[[[2-nitrophenyl]amino]methyl]-4-oxo-3(4H)-
quinazolinyl]- (9CI) (CA INDEX NAME)

09/ 724,941





RN 148472-79-1 CAPLUS

CN Benzenesulfonamide, 4-[4-oxo-2-[(phenylamino)methyl]-3(4H)-quinazolinyl]-
(9CI) (CA INDEX NAME)




RN 148472-80-4 CAPLUS

CN Benzenesulfonamide, 4-[2-[[[(2-chlorophenyl)amino]methyl]-4-oxo-3(4H)-
quinazolinyl]- (9CI) (CA INDEX NAME)



RN 149411-85-8 CAPLUS

CN Benzenesulfonamide, 4-[2-[[[(4-methylphenyl)amino]methyl]-4-oxo-3(4H)-
quinazolinyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1991:656106 CAPLUS

DOCUMENT NUMBER: 115:256106

TITLE: 4-(3H)-quinazolones. Part II: 2-alkyl- or arylaminomethyl-substituted cinnamyl-3-p-(N-phenylthioureidosulfonyl)-4-(3H)-quinazolones

AUTHOR(S): Gaur, V. B.; Shah, V. H.; Parikh, A. R.

CORPORATE SOURCE: Chem. Dep., Saurashtra Univ., Rajkot, 360 005, India


SOURCE: J. Inst. Chem. (India) (1991), 63(2), 66-8

CODEN: JOICA7; ISSN: 0020-3254


DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I



II

AB Title compds. I (R = Ph, substituted Ph, furyl, naphthyl, octadecyl; R1 = CH2NHR, CHBrCHBrPh, CH:CHPh) were prepd. from the **sulfonamide** II. I have bactericidal and fungicidal activity.


IT 137205-41-5P 137205-42-6P 137205-43-7P
137205-44-8P 137205-45-9P 137205-46-0P
137205-47-1P 137205-48-2P 137205-49-3P
137205-50-6P 137205-51-7P 137205-52-8P
137205-53-9P 137205-54-0P 137205-55-1P
137205-56-2P 137205-57-3P 137205-58-4P
137205-59-5P 137205-60-8P 137205-61-9P
137205-62-0P 137205-63-1P 137205-92-6P
137205-93-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 137205-41-5 CAPLUS


CN Benzenesulfonamide, 4-[4-oxo-2-[(phenylamino)methyl]-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)

09/ 724,941




RN 137205-42-6 CAPLUS

CN Benzenesulfonamide, 4-[2-[[4-methylphenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)



RN 137205-43-7 CAPLUS


CN Benzenesulfonamide, 4-[2-[[2-methoxyphenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)



RN 137205-44-8 CAPLUS


CN Benzenesulfonamide, 4-[2-[[3-methoxyphenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)

09/ 724,941




RN 137205-45-9 CAPLUS

CN Benzenesulfonamide, 4-[2-[[4-methoxyphenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)



RN 137205-46-0 CAPLUS


CN Benzenesulfonamide, 4-[2-[[2-nitrophenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)



RN 137205-47-1 CAPLUS


CN Benzenesulfonamide, 4-[2-[[3-nitrophenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)

09/ 724,941





RN 137205-48-2 CAPLUS

CN Benzenesulfonamide, 4-[2-[[[4-nitrophenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)



RN 137205-49-3 CAPLUS


CN Benzenesulfonamide, 4-[2-[[[2-chlorophenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)



RN 137205-50-6 CAPLUS


CN Benzenesulfonamide, 4-[2-[[[3-chlorophenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)

09/ 724,941




RN 137205-51-7 CAPLUS

CN Benzenesulfonamide, 4-[2-[[4-chlorophenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-52-8 CAPLUS

CN Benzenesulfonamide, 4-[4-oxo-2-[[[(phenylmethyl)amino]methyl]-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-53-9 CAPLUS

CN Benzenesulfonamide, 4-[2-[[4-bromophenyl]amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-54-0 CAPLUS

CN Benzenesulfonamide, 4-[2-[(1-naphthalenylamino)methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)



RN 137205-55-1 CAPLUS


CN Benzoic acid, 4-[[[3,4-dihydro-4-oxo-3-[4-[[[(phenylamino)thioxomethyl]amino]sulfonyl]phenyl]-2-quinazolinyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 137205-56-2 CAPLUS


CN Benzoic acid, 4-[[[3,4-dihydro-4-oxo-3-[4-[[[(phenylamino)thioxomethyl]amino]sulfonyl]phenyl]-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)

09/ 724,941




RN 137205-57-3 CAPLUS

CN Benzenesulfonamide, 4-[2-[[[2-(4-carboxyphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)



RN 137205-58-4 CAPLUS


CN Benzenesulfonamide, 4-[2-[[[2-(3-hydroxyphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)



RN 137205-59-5 CAPLUS


CN Benzenesulfonamide, 4-[2-[[[2-(4-hydroxyphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)

09/ 724,941




RN 137205-60-8 CAPLUS

CN Benzenesulfonamide, 4-[2-[(cyclohexylamino)methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 137205-61-9 CAPLUS

CN Benzenesulfonamide, 4-[2-[(methylamino)methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)



RN 137205-62-0 CAPLUS


CN Benzenesulfonamide, 4-[2-[(butylamino)methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)



RN 137205-63-1 CAPLUS



CN Benzenesulfonamide, 4-[2-[(octadecylamino)methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)

09/ 724,941




RN 137205-92-6 CAPLUS

CN Benzenesulfonamide, 4-[2-[[2-(2-methylphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)



RN 137205-93-7 CAPLUS

CN Benzenesulfonamide, 4-[2-[[2-(3-methylphenyl)amino]methyl]-4-oxo-3(4H)-quinazolinyl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1989:514965 CAPLUS

DOCUMENT NUMBER: 111:114965

TITLE: Preparation of (carboxamidomethyl)
cephemcarboxylic acids as antibiotics

INVENTOR(S): Arnould, Jean Claude; Jung, Frederick Henri;
Boucherot, Dominique; Strawson, Colin John; Davies,
David Huw

PATENT ASSIGNEE(S): Imperial Chemical Industries PLC, UK; ICI-Pharma S. A.

SOURCE: Eur. Pat. Appl., 78 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 304158	A1	19890222	EP 1988-306420	19880713
EP 304158	B1	19940622		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
HU 47942	A2	19890428	HU 1988-3692	19880715
HU 201949	B	19910128		
FI 8803439	A	19890124	FI 1988-3439	19880720
ZA 8805271	A	19890329	ZA 1988-5271	19880720
DK 8804148	A	19890124	DK 1988-4148	19880722
NO 8803275	A	19890124	NO 1988-3275	19880722
AU 8819762	A1	19890127	AU 1988-19762	19880722
JP 01093592	A2	19890412	JP 1988-182006	19880722
CN 1031378	A	19890301	CN 1988-106393	19880723
US 5019570	A	19910528	US 1988-223988	19880725
US 5232918	A	19930803	US 1991-653149	19910211
US 5371220	A	19941206	US 1992-886392	19920521
PRIORITY APPLN. INFO.:			EP 1987-401718	19870723
			US 1988-223988	19880725
			US 1991-653149	19910211

OTHER SOURCE(S): MARPAT 111:114965

GI For diagram(s), see printed CA Issue.

AB Cephalosporins having Q as a 3-position substituent [R1 = H, (substituted) C1-6 alkyl, etc.; Het = 5- or 6-membered heterocyclic ring Q1, Q2; A = CH, N; B = O, S, etc.; 1 or 2 of D, E, F, and G = N, the remainder = CH; or Het = pyrazinone, pyridinone, etc.; Het is fused by any 2 adjacent C atoms to the benzene ring and is bonded via a C atom to the CH2NR1CO group; R2, R3 = OH, in vivo hydrolyzable ester thereof; R3 is ortho to R2] were prepd. as antibiotics. Reaction of 6,7-bis(phenylacetoxy)-1,4-dihydro-1-ethyl-4-oxoquinoline-3-carbonyl chloride with 3-(aminomethyl)-7-[2-(2-amino-4-thiazolyl)-2-[(Z)-[(1-carboxy-1-methylethoxy)imino]acetamido]ceph-3-em-4-carboxylic acid in DMF contg. Et3N, followed by deprotection and workup, gave 7-[2-(2-amino-4-thiazolyl)-2-[(Z)-[(1-carboxy-1-methylethoxy)imino]acetamido]-3-[(1,4-dihydro-1-ethyl-6,7-dihydroxy-4-oxoquinolin-3-carboxamido)methyl]ceph-3-em-4-carboxylic acid (I). I had min. inhibitory concns. of 0.008 .mu.g/mL and 16 .mu.g/mL, resp., against Escherichia coli DCO and Staphylococcus aureus 147 N.


IT 122234-19-9P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. of, as antibiotic)

RN 122234-19-9 CAPLUS

CN 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,
 7-[[[(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-3-[[[(1,4-dihydro-6,7-dihydroxy-4-oxo-2-quinazolinyl)carbonyl]amino]methyl]-8-oxo-, [6R-[6.alpha.,7.beta.(Z)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.

—CO₂H

L5 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1989:135739 CAPLUS
 DOCUMENT NUMBER: 110:135739
 TITLE: Preparation of 4-amino-3-hydroxy-5-cyclohexylpentanoyl-
 containing peptides as renin inhibitors
 INVENTOR(S): Gante, Joachim; Raddatz, Peter; Sombroek, Johannes;
 Schmitges, Claus J.; Minck, Klaus Otto
 PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Fed. Rep. Ger.
 SOURCE: Ger. Offen., 17 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3721855	A1	19880922	DE 1987-3721855	19870702
EP 286813	A2	19881019	EP 1988-102971	19880229
EP 286813	A3	19901212		
R: AT, BE, CH, DE, ES, FR, GB, IT, LI, NL, SE				
AU 8812617	A1	19880915	AU 1988-12617	19880301
AU 614951	B2	19910919		
JP 63258451	A2	19881025	JP 1988-56504	19880311
ZA 8801782	A	19881026	ZA 1988-1782	19880311
HU 49147	A2	19890828	HU 1988-1191	19880311

HU 204848 B 19920228
 PRIORITY APPLN. INFO.:

DE 1987-3707879 19870312
 DE 1987-3721855 19870702

OTHER SOURCE(S): MARPAT 110:135739

AB X-Z-NR2-CHR3-CR4-(CHR5)_n-CO-E-NR6-D [I; X = H, R1O(CH₂)_mCO, R1SO₂, etc.; Z = 0-4 amino acid residues chosen from Abu, Ada, Ala, .beta.-Ala, Arg, Asn, Asp, Bia, Cal, Dab, Gln, Glu, Gly, His, N(i.m.)-alkyl-His, Ile, Leu, tert-Leu, Lys, Met, .alpha.-Nal, .beta.-Nal, Nbg, Nle, Orn, Phe, Pro, Ser, Thr, Tic, Trp, Tyr, Val; E = 0-2 amino acid residues chosen from Abu, Ala, Cal, His, Ile, Leu, Met, Nle, Phe, Trp, Tyr, Val; D = CH₂CH(OH)CH₂OH, (CH₂)_zSO₂R₇, phenylalkyl, furylalkyl, thienylalkyl, pyridylalkyl, etc.; R₁, R₃ = H, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl, (substituted) C₃-7 cycloalkyl, etc.; R₂, R₅, R₆ = H, alkyl; R₄ = :O, (H,OH), (H,NH₂); R₇ = OH, alkoxy, amino; m = 0-5; n = 1, 2; z = 2-6; Bia = 3-(2-benzimidazolyl)alanyl; Cal = 3-cyclohexylalanyl; Dab = 2,4-diaminobutyryl; .alpha.-Nal = .alpha.-naphthylalanyl; .beta.-Nal = .beta.-naphthylalanyl; Nbg = (2-norbornyl)glycyl; Tic = tetrahydroisoquinoliny-1-**carbonyl**], useful as renin inhibitors (no data), were prepd. 2-[1S-(3S-Hydroxy-4S-(N-tert-butoxycarbonylphenylalanylhystidylamino)-5-cyclohexylpentanoylamino)-3-methylbutyl]-3H-quinazolin-4-one was prepd. by the soln. phase method.


IT 119422-52-5

RL: RCT (Reactant)

(hydrogenolysis of, in prepn. of renin inhibitor)

RN 119422-52-5 CAPLUS

CN L-threo-Pentonamide, 5-cyclohexyl-2,4,5-trideoxy-N-[1-(1,4-dihydro-4-oxo-2-quinazolinyl)-3-methylbutyl]-4-[[N-[N-[(phenylmethoxy)carbonyl]-L-phenylalanyl]-L-histidyl]amino]-, (S)- (9CI) (CA INDEX NAME)




IT 119422-45-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and reaction of, in prepn. of renin inhibitor)

RN 119422-45-6 CAPLUS

CN L-threo-Pentonamide, N-[1-(3-amino-3,4-dihydro-4-oxo-2-quinazolinyl)-2-methylbutyl]-5-cyclohexyl-2,4,5-trideoxy-4-[[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl]-1-[(phenylmethoxy)methyl]-L-histidyl]amino]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)




IT 119422-33-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as intermediate for renin inhibitor)

RN 119422-33-2 CAPLUS

CN L-threo-Pentonamide, 5-cyclohexyl-2,4,5-trideoxy-N-[1-(1,4-dihydro-4-oxo-2-quinazolinyl)-3-methylbutyl]-4-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl]-1-(2,4-dinitrophenyl)-L-histidyl]amino]-, (S)- (9CI) (CA INDEX NAME)



IT 119422-16-1P 119422-17-2P 119422-18-3P

119422-19-4P 119422-23-0P 119422-24-1P


119422-25-2P 119422-30-9P 119422-31-0P

119422-32-1P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of, as renin inhibitor)


RN 119422-16-1 CAPLUS

CN L-threo-Pentonamide, 5-cyclohexyl-2,4,5-trideoxy-N-[1-(1,4-dihydro-4-oxo-2-quinazolinyl)-2-methylbutyl]-4-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl]-L-histidyl]amino]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)




RN 119422-17-2 CAPLUS

CN L-threo-Pentonamide, N-[1-(3-amino-3,4-dihydro-4-oxo-2-quinazolinyl)-2-methylbutyl]-5-cyclohexyl-2,4,5-trideoxy-4-[[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl]-L-histidyl]amino]-, [S-(R*,R*)]-(9CI) (CA INDEX NAME)




RN 119422-18-3 CAPLUS

CN L-threo-Pentonamide, 5-cyclohexyl-2,4,5-trideoxy-N-[1-(1,4-dihydro-4-oxo-2-quinazolinyl)-3-methylbutyl]-4-[[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl]-L-histidyl]amino]-, (S)- (9CI) (CA INDEX NAME)




RN 119422-19-4 CAPLUS

CN L-threo-Pentonamide, N-[1-(3-amino-3,4-dihydro-4-oxo-2-quinazolinyl)-3-methylbutyl]-5-cyclohexyl-2,4,5-trideoxy-4-[[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl]-L-histidyl]amino]-, (S)- (9CI)
(CA INDEX NAME)




RN 119422-23-0 CAPLUS

CN L-threo-Pentonamide, N-[1-(3-amino-3,4-dihydro-4-oxo-2-quinazolinyl)ethyl]-5-cyclohexyl-2,4,5-trideoxy-4-[[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl]-L-histidyl]amino]-, (S)- (9CI) (CA INDEX NAME)




RN 119422-24-1 CAPLUS

CN L-threo-Pentonamide, N-[1-(3-amino-3,4-dihydro-4-oxo-2-quinazolinyl)-2-methylpropyl]-5-cyclohexyl-2,4,5-trideoxy-4-[[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl]-L-histidyl]amino]-, (S)- (9CI)
(CA INDEX NAME)




RN 119422-25-2 CAPLUS

CN L-threo-Pentonamide, N-[1-(3-amino-3,4-dihydro-4-oxo-2-quinazolinyl)-2-phenylethyl]-5-cyclohexyl-2,4,5-trideoxy-4-[[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl]-L-histidyl]amino]-, (S)- (9CI)
(CA INDEX NAME)




RN 119422-30-9 CAPLUS

CN L-threo-Pentonamide, N-[1-(3-amino-3,4-dihydro-4-oxo-2-quinazolinyl)-2-methylbutyl]-5-cyclohexyl-2,4,5-trideoxy-4-[[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl]glycyl]amino]-, [S-(R*,R*)]- (9CI)
(CA INDEX NAME)




RN 119422-31-0 CAPLUS

CN L-threo-Pentonamide, 5-cyclohexyl-2,4,5-trideoxy-N-[1-(1,4-dihydro-4-oxo-2-quinazolinyl)-3-methylbutyl]-4-[(N-L-phenylalanyl-L-histidyl)amino]-, (S)-(9CI) (CA INDEX NAME)



RN 119422-32-1 CAPLUS

CN L-Histidinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N-[2-amino-1-(cyclohexylmethyl)-4-[[[1-(1,4-dihydro-4-oxo-2-quinazolinyl)-3-methylbutyl]amino]-4-oxobutyl]-, [1S-[1R*,2R*,4(R*)]]- (9CI) (CA INDEX NAME)



IT 119422-35-4P 119422-36-5P 119422-37-6P
119422-38-7P 119422-39-8P 119422-42-3P
119422-43-4P


RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as renin inhibitor intermediate)

RN 119422-35-4 CAPLUS

CN Carbamic acid, [1-(3-amino-3,4-dihydro-4-oxo-2-quinazolinyl)-3-methylbutyl]-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09/ 724,941



RN 119422-36-5 CAPLUS

CN Carbamic acid, [1-(1,4-dihydro-4-oxo-2-quinazolinyl)-3-methylbutyl]-, 1,1-dimethylethyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 119422-37-6 CAPLUS

CN 4(1H)-Quinazolinone, 2-(1-amino-3-methylbutyl)-, dihydrochloride, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




O₂ HCl

RN 119422-38-7 CAPLUS

CN L-threo-Pentonamide, 5-cyclohexyl-2,4,5-trideoxy-N-[1-(1,4-dihydro-4-oxo-2-quinazolinyl)-3-methylbutyl]-4-[[(1,1-dimethylethoxy) carbonyl] amino]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/ 724,941



RN 119422-39-8 CAPLUS


CN L-threo-Pentonamide, 5-cyclohexyl-2,4,5-trideoxy-N-[1-(1,4-dihydro-4-oxo-2-quinazolinyl)-3-methylbutyl]-4-[[2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-[1-(2,4-dinitrophenyl)-1H-imidazol-4-yl]-1-oxopropyl]amino]-, [1(S),4(S)]-(9CI) (CA INDEX NAME)



RN 119422-42-3 CAPLUS

CN Carbamic acid, [1-(3-amino-3,4-dihydro-4-oxo-2-quinazolinyl)-2-methylbutyl]-, 1,1-dimethylethyl ester, [S-(R*,R*)]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 119422-43-4 CAPLUS

CN 4(3H)-Quinazolinone, 3-amino-2-(1-amino-2-methylbutyl)-, [S-(R*,R*)]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 119422-53-6

RL: RCT (Reactant)

(reaction of, in prepn. of renin inhibitor)

RN 119422-53-6 CAPLUS

CN L-Histidinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N-[1-(cyclohexylmethyl)-4-[[1-(1,4-dihydro-4-oxo-2-quinazolinyl)-3-methylbutyl]amino]-2,4-dioxobutyl]-, [S-(R*,R*)]- (9CI) (CA INDEX NAME)



L5 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1988:112384 CAPLUS

DOCUMENT NUMBER: 108:112384

TITLE: Synthesis of some new 4-quinazolinone-2-carboxylic acid esters, -2-carboxamides, -2-carbohydrazides and their tosyl derivatives having potential biological activity

AUTHOR(S): Joshi, Vidya; Chaudhari, Rajendra P.

CORPORATE SOURCE: Dep. Org. Chem., Inst. Sci., Bombay, 400 032, India

SOURCE: Indian J. Chem., Sect. B (1987), 26B(6), 602-4



CODEN: IJSBDB; ISSN: 0376-4699

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 108:112384


GI



- AB Quinazolinecarbohydrazides I [R1 = H, Me, OMe, halo, and R2 = H; R1R2 = (CH2O2)] were prepd. from the resp. anthranilamides by cyclocondensation with EtO2CCO2Et and subsequent amidation with N2H4; I showed antitubercular activity. Also prepd. were tosyl derivs. II.
- IT 34632-71-8P 113124-33-7P 113124-34-8P
113124-35-9P 113144-38-0P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and antitubercular activity of)
- RN 34632-71-8 CAPLUS
- CN 2-Quinazolinecarboxylic acid, 1,4-dihydro-4-oxo-, hydrazide (9CI) (CA INDEX NAME)




- RN 113124-33-7 CAPLUS
- CN 2-Quinazolinecarboxylic acid, 1,4-dihydro-7-methoxy-4-oxo-, hydrazide (9CI) (CA INDEX NAME)




- RN 113124-34-8 CAPLUS
- CN 2-Quinazolinecarboxylic acid, 7-chloro-1,4-dihydro-4-oxo-, hydrazide (9CI) (CA INDEX NAME)


09/ 724,941




RN 113124-35-9 CAPLUS
CN 2-Quinazolinecarboxylic acid, 7-bromo-1,4-dihydro-4-oxo-, hydrazide (9CI)
(CA INDEX NAME)



RN 113144-38-0 CAPLUS
CN 2-Quinazolinecarboxylic acid, 1,4-dihydro-7-methyl-4-oxo-, hydrazide (9CI)
(CA INDEX NAME)




IT 76617-97-5P 113124-28-0P 113124-29-1P
113124-30-4P 113124-31-5P 113124-36-0P
113124-38-2P 113124-39-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 76617-97-5 CAPLUS
CN 2-Quinazolinecarboxamide, 1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 113124-28-0 CAPLUS
CN 2-Quinazolinecarboxamide, 1,4-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

09/ 724,941




RN 113124-29-1 CAPLUS

CN 2-Quinazolinecarboxamide, 1,4-dihydro-7-methoxy-4-oxo- (9CI) (CA INDEX NAME)




RN 113124-30-4 CAPLUS

CN 2-Quinazolinecarboxamide, 7-chloro-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 113124-31-5 CAPLUS

CN 2-Quinazolinecarboxamide, 7-bromo-1,4-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 113124-36-0 CAPLUS


CN 2-Quinazolinecarboxylic acid, 1,4-dihydro-4-oxo-, 2-[(4-methylphenyl)sulfonyl]hydrazide (9CI) (CA INDEX NAME)




RN 113124-38-2 CAPLUS
 CN 2-Quinazolinecarboxylic acid, 1,4-dihydro-7-methyl-4-oxo-,
 2-[(4-methylphenyl)sulfonyl]hydrazide (9CI) (CA INDEX NAME)



RN 113124-39-3 CAPLUS
 CN 2-Quinazolinecarboxylic acid, 1,4-dihydro-7-methoxy-4-oxo-,
 2-[(4-methylphenyl)sulfonyl]hydrazide (9CI) (CA INDEX NAME)



L5 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2002 ACS
 ACCESSION NUMBER: 1983:405584 CAPLUS
 DOCUMENT NUMBER: 99:5584
 TITLE: Synthesis and biological activities of certain
 derivatives of 3-aryl-4(3H)-quinazolinones. Part I
 AUTHOR(S): Shankar, C. Ravi; Rao, A. Devendar; Reddy, B.
 Jayasena; Reddy, V. Malla
 CORPORATE SOURCE: Univ. Coll. Pharm. Sci., Kakatiya Univ., Warangal, 506
 009, India
 SOURCE: J. Indian Chem. Soc. (1983), 60(1), 61-3
 CODEN: JICSAH; ISSN: 0019-4522
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 99:5584
 GI



AB Nine different 3-aryl-2-(N',N'-substituted aminomethyl)-4(3H)-quinazolinones have been synthesized by condensing 3-aryl-2-chloromethyl-4(3H)-quinazolinones with different secondary bases. Similarly, seven different 3-aryl-2-(N4-arylsulfonamidomethyl)-4(3H)-quinazolinones, e.g. I, have been obtained on reacting 3-aryl-2-chloromethyl-4-(3H)-quinazolinones with various aryl **sulfonamides**. The antibacterial and antifungal activities of the compds. have been detd. and the structure-activity relationships is discussed.

IT 86109-92-4P 86109-93-5P 86109-94-6P

86109-97-9P 86109-98-0P 86109-99-1P


86110-00-1P 86110-01-2P 86110-02-3P

86110-03-4P 86110-04-5P 86110-05-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn., bactericidal, and fungicidal activity of)


RN 86109-92-4 CAPLUS

CN 4(3H)-Quinazolinone, 2-[(diethylamino)methyl]-3-(4-methylphenyl)- (9CI)
(CA INDEX NAME)



RN 86109-93-5 CAPLUS


CN 4(3H)-Quinazolinone, 2-[(dimethylamino)methyl]-3-(4-methylphenyl)- (9CI)
(CA INDEX NAME)



RN 86109-94-6 CAPLUS


CN 4(3H)-Quinazolinone, 2-[[bis(2-hydroxyethyl)amino]methyl]-3-(4-methylphenyl)- (9CI) (CA INDEX NAME)

09/ 724,941




RN 86109-97-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-[(diethylamino)methyl]-3-(4-methoxyphenyl)- (9CI)
(CA INDEX NAME)




RN 86109-98-0 CAPLUS

CN 4(3H)-Quinazolinone, 2-[(dimethylamino)methyl]-3-(4-methoxyphenyl)- (9CI)
(CA INDEX NAME)



RN 86109-99-1 CAPLUS


CN Benzenesulfonamide, 4-[[[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 86110-00-1 CAPLUS


CN Benzenesulfonamide, 4-[[[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-N-(2,6-dimethoxy-4-pyrimidinyl)- (9CI) (CA INDEX NAME)

09/ 724,941




RN 86110-01-2 CAPLUS

CN Benzenesulfonamide, 4-[[[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-N-(5-methyl-1,3,4-thiadiazol-2-yl)- (9CI) (CA INDEX NAME)




RN 86110-02-3 CAPLUS

CN Benzenesulfonamide, 4-[[[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-N-4-pyrimidinyl- (9CI) (CA INDEX NAME)



RN 86110-03-4 CAPLUS


CN Acetamide, N-[[4-[[[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 86110-04-5 CAPLUS

CN Benzenesulfonamide, 4-[[[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]-N-(2,6-dimethyl-4-pyrimidinyl)- (9CI) (CA INDEX NAME)

09/ 724,941





RN 86110-05-6 CAPLUS
CN Benzenesulfonamide, N-(aminoiminomethyl)-4-[[[3,4-dihydro-3-(4-methylphenyl)-4-oxo-2-quinazolinyl]methyl]amino]- (9CI) (CA INDEX NAME)



L5 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1983:55550 CAPLUS
DOCUMENT NUMBER: 98:55550
TITLE: Disazo dyes
INVENTOR(S): Kurtz, Walter; Lamm, Tunther
PATENT ASSIGNEE(S): BASF A.-G. , Fed. Rep. Ger.
SOURCE: Ger. Offen., 216 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3111937	A1	19821007	DE 1981-3111937	19810326
EP 62200	A1	19821013	EP 1982-102278	19820319
EP 62200	B1	19850123		
R: CH, DE, FR, GB, IT				
JP 57167354	A2	19821015	JP 1982-43011	19820319
PRIORITY APPLN. INFO.:			DE 1981-3111937	19810326

GI




AB Disazo dyes (I, R = diazo component residue; R1 = CN, CO2R4, COSR5, CONR4R5, morpholinocarbonyl, piperidinylcarbonyl, pyrrolidinylcarbonyl, piperazinylcarbonyl, optionally substituted 1,2,4-thiadiazolyl, oxadiazolyl; R2 = H, Cl, Br, alkoxy, PhO, alkyl, AcNH, dialkylamino, CO2H, NO2; R3 = a coupling component residue, except pyridones; R4 = H, R5; R5 = optionally substituted alkyl, alkenyl, cycloalkyl, or aryl; n = 1, 2; m = 0, 1, 2, 3, 4) were prep'd. and were used to dye cotton, polyester fibers, their blends, polyamide and acrylic fibers, and leather fast yellow to blue shades. Thus, Et 2-amino-5-[(4-chlorophenyl)azo]benzoate [80162-91-0] was diazotized and coupled with 1-(3-chlorophenyl)-3-methyl-5-pyrazolone [90-31-3] to give II [84267-20-9], dyeing a cotton-polyester blend a fast yellow shade. Numerous other I were prep'd.

IT **84266-80-8P 84266-98-8P 84342-68-7P**

RL: IMF (Industrial manufacture); PREP (Preparation)
(prepn. of)

RN 84266-80-8 CAPLUS


CN Benzoic acid, 5-[(2-chlorophenyl)azo]-2-[[1-[[[4-[(1,4-dihydro-4-oxo-2-quinazolinyl)carbonyl]amino]phenyl]amino]carbonyl]-2-oxopropyl]azo]-, 1-methylethyl ester (9CI) (CA INDEX NAME)



RN 84266-98-8 CAPLUS

CN Benzoic acid, 5-[(4-chlorophenyl)azo]-2-[[1-[[[4-[(1,4-dihydro-4-oxo-2-quinazolinyl)carbonyl]amino]phenyl]amino]carbonyl]-2-oxopropyl]azo]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—Cl

RN 84342-68-7 CAPLUS

CN Benzoic acid, 5-[(2,4-dichlorophenyl)azo]-2-[[1-[[[4-[[[1,4-dihydro-4-oxo-2-quinazolinyl)carbonyl]amino]phenyl]amino]carbonyl]-2-oxopropyl]azo]-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—Cl

09/ 724,941

ACCESSION NUMBER: 1981:549701 CAPLUS
DOCUMENT NUMBER: 95:149701
TITLE: Ionization constants of arenesulfhydrazides of
3-R-quinazolin-4-one-2-carboxylic acid
AUTHOR(S): Bezuglyi, P. A.; Chernykh, V. P.; Makurina, V. I.;
Sopel'nik, E. M.
CORPORATE SOURCE: Khar'k. Farm. Inst., Kharkov, USSR
SOURCE: Soobshch. Akad. Nauk Gruz. SSR (1981), 102(1), 77-80
CODEN: SAKNAH; ISSN: 0002-3167
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI




AB The ionization consts. of I (R, R1 = MeO, Me, H, Br, Cl, NO2) and their conjugate acids were linearly correlated with Hammett .sigma. consts.; .rho. was neg. in all cases. R1 had a greater effect than R on the pKa of I.

IT 79342-90-8 79342-91-9 79342-92-0
79342-93-1 79342-94-2 79342-95-3
79342-96-4 79342-97-5 79342-98-6
79342-99-7 79343-00-3

RL: PRP (Properties)
(ionization consts. of)


RN 79342-90-8 CAPLUS

CN 2-Quinazolinecarboxylic acid, 3,4-dihydro-4-oxo-3-phenyl-,
2-[(4-nitrophenyl)sulfonyl]hydrazide (9CI) (CA INDEX NAME)



RN 79342-91-9 CAPLUS


CN 2-Quinazolinecarboxylic acid, 3,4-dihydro-4-oxo-3-phenyl-,
2-[(4-chlorophenyl)sulfonyl]hydrazide (9CI) (CA INDEX NAME)



RN 79342-92-0 CAPLUS


09/ 724,941

CN 2-Quinazolinecarboxylic acid, 3,4-dihydro-4-oxo-3-phenyl-,
2-[(4-bromophenyl)sulfonyl]hydrazide (9CI) (CA INDEX NAME)




RN 79342-93-1 CAPLUS

CN 2-Quinazolinecarboxylic acid, 3,4-dihydro-4-oxo-3-phenyl-,
2-[(4-methylphenyl)sulfonyl]hydrazide (9CI) (CA INDEX NAME)




RN 79342-94-2 CAPLUS

CN 2-Quinazolinecarboxylic acid, 3,4-dihydro-4-oxo-3-phenyl-,
2-[(4-methoxyphenyl)sulfonyl]hydrazide (9CI) (CA INDEX NAME)



RN 79342-95-3 CAPLUS


CN 2-Quinazolinecarboxylic acid, 3,4-dihydro-3-(4-nitrophenyl)-4-oxo-,
2-(phenylsulfonyl)hydrazide (9CI) (CA INDEX NAME)



RN 79342-96-4 CAPLUS


CN 2-Quinazolinecarboxylic acid, 3-(4-chlorophenyl)-3,4-dihydro-4-oxo-,
2-(phenylsulfonyl)hydrazide (9CI) (CA INDEX NAME)

09/ 724,941




RN 79342-97-5 CAPLUS

CN 2-Quinazolinecarboxylic acid, 3-(4-bromophenyl)-3,4-dihydro-4-oxo-,
2-(phenylsulfonyl)hydrazide (9CI) (CA INDEX NAME)




RN 79342-98-6 CAPLUS

CN 2-Quinazolinecarboxylic acid, 3,4-dihydro-4-oxo-3-phenyl-,
2-(phenylsulfonyl)hydrazide (9CI) (CA INDEX NAME)




RN 79342-99-7 CAPLUS

CN 2-Quinazolinecarboxylic acid, 3,4-dihydro-3-(4-methylphenyl)-4-oxo-,
2-(phenylsulfonyl)hydrazide (9CI) (CA INDEX NAME)



RN 79343-00-3 CAPLUS

CN 2-Quinazolinecarboxylic acid, 3,4-dihydro-3-(4-methoxyphenyl)-4-oxo-,
2-(phenylsulfonyl)hydrazide (9CI) (CA INDEX NAME)



L5 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1970:66886 CAPLUS

DOCUMENT NUMBER: 72:66886

TITLE: 2-Hydrazinomethylquinazoline-4-one and
2-mercaptomethylquinazoline-4-one and their reactions

AUTHOR(S): Lubimowski, Boleslaw; Berezowski, Lubomir

CORPORATE SOURCE: Akad. Med., Cracow, Poland

SOURCE: Acta Pol. Pharm. (1969), 26(4), 293-300

CODEN: APPHAX

DOCUMENT TYPE: Journal

LANGUAGE: Polish

GI For diagram(s), see printed CA Issue.

AB Several derivs. of 4(3H)-quinazolinone were prepd. as compds. with potential biol. activity. I (0.19 g), 5 ml C₅H₅N, 5 ml 95% EtOH, and 1 ml 85% NH₂NH₂.H₂O was refluxed 2 hr to yield 78.7% II, m. 185-6.degree. (H₂O); picrate m. 197-8.degree. (EtOH). Similarly, I and PhNHNH₂ gave 94.1% III, m. 280-1.degree. (EtOH); picrate m. 255.5-6.degree. (EtOH). II refluxed in EtOH with 10% excess of **carbonyl** compds. gave the following IV [R₁, % yield, and m.p. (EtOH) given]: 4-Me₂NC₆H₄CH, 59.3, 250.5-1.5.degree.; 2-Cl₁₀H₇CH, 82.9, 263-4.degree.; PhCH, 85.5, 228-9.degree.; furfurylidene, 72, 203-4.degree.; Me₂C, 90, 214-16.degree.; PhMeC, 67, 204-5.degree.. I (0.19 g) in 10 ml hot EtOH was treated with 0.19 g thiourea in 5 ml EtOH and the mixt. refluxed 3 hr to yield 85.5% V, m. 164.5-5.5.degree. (MeOH). When the same reactants were refluxed 30 min with 0.01 g KI and then 30 min with 0.2 g picric acid, 82% V picrate, m. 209-10.degree. (EtOH), was obtained. V (1.7 g) (or 0.97 g VI) and 20 ml MeOH or EtOH was refluxed 1 hr to yield 83.3% VIII, m. 212.5-13.5.degree. (C₅H₅N). V (0.23 g), 1.5-2.0 ml 0.5M KOH in EtOH, and 15 ml 95% EtOH refluxed 1 hr yielded 70% VI, m. 191-2.degree.. VI was also prepd. when 1.95 g I in 50 ml EtOH and 2.5 g Na₂S₂O₃ .5H₂O in 40 ml H₂O was refluxed .apprx.30 min and worked up. VI (0.19 g), in 1 ml 10% NaOH and 5 ml EtOH, treated with 0.2 g 2,4 -(O₂N)₂C₆H₃Cl in 5 ml EtOH, and the mixt. refluxed 10 min yielded 84% VII, which slowly decompd. on heating. In biol. tests, II inhibited monoamine oxidase in 10⁻⁴-10⁻²M solns., but III was inactive.

IT 19062-56-7P 25816-09-5P 25816-10-8P

25816-11-9P 25816-12-0P 25816-13-1P

25816-14-2P 25816-15-3P 26032-94-0P


26032-95-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 19062-56-7 CAPLUS

CN 4(3H)-Quinazolinone, 2-[(2-phenylhydrazino)methyl]- (8CI) (CA INDEX NAME)


09/ 724,941



RN 25816-09-5 CAPLUS
CN 4(3H)-Quinazolinone, 2-(hydrazinomethyl)-, monopicrate (8CI) (CA INDEX NAME)


CM 1

CRN 26032-94-0
CMF C9 H10 N4 O



CM 2


CRN 88-89-1
CMF C6 H3 N3 O7



RN 25816-10-8 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(2-phenylhydrazino)methyl]-, monopicrate (8CI) (CA INDEX NAME)

CM 1

CRN 19062-56-7
CMF C15 H14 N4 O




09/ 724,941

CM 2


CRN 88-89-1

CMF C6 H3 N3 O7




RN 25816-11-9 CAPLUS

CN Benzaldehyde, p-(dimethylamino)-, [(3,4-dihydro-4-oxo-2-quinazolinyl)methyl]hydrazone (8CI) (CA INDEX NAME)




RN 25816-12-0 CAPLUS

CN 2-Naphthaldehyde, [(3,4-dihydro-4-oxo-2-quinazolinyl)methyl]hydrazone (8CI) (CA INDEX NAME)



RN 25816-13-1 CAPLUS


CN Benzaldehyde, [(3,4-dihydro-4-oxo-2-quinazolinyl)methyl]hydrazone (8CI) (CA INDEX NAME)




RN 25816-14-2 CAPLUS

CN 2-Furaldehyde, [(3,4-dihydro-4-oxo-2-quinazolinyl)methyl]hydrazone (8CI) (CA INDEX NAME)


09/ 724,941




RN 25816-15-3 CAPLUS
CN 4(3H)-Quinazolinone, 2-[(isopropylidenehydrazino)methyl]- (8CI) (CA INDEX NAME)



RN 26032-94-0 CAPLUS
CN 4(3H)-Quinazolinone, 2-(hydrazinomethyl)- (8CI) (CA INDEX NAME)



RN 26032-95-1 CAPLUS
CN 4(3H)-Quinazolinone, 2-[[(.alpha.-methylbenzylidene)hydrazino]methyl]- (8CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 10:36:56 ON 22 JUL 2002)

FILE 'REGISTRY' ENTERED AT 10:37:20 ON 22 JUL 2002

L1 STRUCTURE UPLOADED

L2 50 S L1

L3 36714 S L1 FUL

09/ 724,941

FILE 'CAPLUS' ENTERED AT 10:39:42 ON 22 JUL 2002

L4 248 S L3

L5 21 S L4 AND (CARBONYL OR CARBOXAMID? OR SULFON?)

=> s l4 and (proliferati? or ksp or cancer? or hyperplasia)

151085 PROLIFERATI?

743 KSP

173658 CANCER?

18885 HYPERPLASIA

L6 6 L4 AND (PROLIFERATI? OR KSP OR CANCER? OR HYPERPLASIA)

=> s l6 not l5

L7 5 L6 NOT L5

=> d l7 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N):y

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:293477 CAPLUS

DOCUMENT NUMBER: 136:304056

TITLE: Hedgehog antagonists, methods and uses related thereto

INVENTOR(S): Dudek, Henryk; Pepicelli, Carmen; Karavanov, Irina

PATENT ASSIGNEE(S): Curis, Inc., USA

SOURCE: PCT Int. Appl., 224 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030462	A2	20020418	WO 2001-US32100	20011015
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2000-240564P P 20001013

AB The present application is directed to compns. and methods for inhibiting angiogenesis and treating or preventing unwanted cell **proliferation**, including tumors, by inhibiting the hedgehog pathway, e.g., with an antagonist of the hedgehog pathway such as those disclosed herein. In one embodiment, the subject methods may be used to inhibit unwanted cell **proliferation** by detg. whether cells overexpress a gli gene, and contacting cells that overexpress gli gene with an effective amt. of a hedgehog antagonist. In preferred embodiments, the unwanted cell **proliferation** is **cancer** or benign prostatic **hyperplasia**. Another aspect of the present invention involves measuring the levels of gli gene expression in order detn. the likelihood that a **cancer** will develop or to detn. a **cancer** treatment protocol. Another embodiment of the invention involves methods for using hedgehog antagonists to stimulate surfactant prodn. or lamellated body formation in lung cells, esp. the lung cells of premature infants. In other preferred embodiments, hedgehog antagonists are selected from small mols., hedgehog antibodies, antisense nucleic acids and ribozymes.

IT 330796-27-5


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(hedgehog pathway antagonists for inhibition of unwanted cell
proliferation in cells overexpressing gli gene or to stimulate
surfactant prodn. in lung for treatment of premature infants)

RN 330796-27-5 CAPLUS

CN Urea, N-[1-[3-(4-fluorophenyl)-3,4-dihydro-4-oxo-2-quinazolinyl]ethyl]-N-methyl-N'-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:935583 CAPLUS

DOCUMENT NUMBER: 136:53759

TITLE: Preparation of N-acylquinazolinonealkylamines as
KSP kinesin inhibitorsINVENTOR(S): Finer, Jeffrey T.; Bergnes, Gustav; Feng, Bainian;
Smith, Whitney W.; Chabala, John C.; Morgans, David
J., Jr.

PATENT ASSIGNEE(S): Cytokinetics, Inc., USA

SOURCE: PCT Int. Appl., 179 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001098278	A1	20011227	WO 2001-US13901	20010427
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2000-213104P P 20000621

US 2000-699047 A 20001024

OTHER SOURCE(S): MARPAT 136:53759

GI



AB R1CR2R2'NRR4 [I; R = H, COR3, SO2R3', CH2R3''; R1 = (un)substituted 3,4-dihydro-4-oxoquinazolin-2-yl; R2,R2' = H, (oxa)alkyl, (hetero)aryl, etc.; R3 = H, alkyl, alkoxy, (hetero)aryl, etc.; R3',R4 = H, alkyl, (hetero)aryl, etc.; R3'' = alkyl, (hetero)aryl, etc.] were prepd. Thus, 2-(H2N)C6H4CO2H was amidated by PrCOCl and the cyclized product cyclocondensed with PhCH2NH2 to give, after bromination, quinazolinone II (R = Br) which was converted in 2 steps to II [R = N(COC6H4F-4)CH2CH2NMe2]. Data for biol. activity of I were given.

IT 288261-76-7P 288261-77-8P 289672-01-1P
 299444-93-2P 299446-39-2P 299446-79-0P
 303212-68-2P 303212-84-2P 334003-55-3P
 334488-92-5P 334488-94-7P 334488-97-0P
 334488-98-1P 334488-99-2P 334489-01-9P
 334489-06-4P 334495-83-9P 334495-89-5P
 334654-66-9P 334654-69-2P 334654-77-2P
 334654-79-4P 334654-82-9P 334654-87-4P
 334770-11-5P 334801-46-6P 334801-62-6P
 334801-63-7P 334810-13-8P 334810-27-4P
 335102-45-9P 335102-48-2P 335102-52-8P
 335109-60-9P 335109-66-5P 335109-86-9P
 335109-90-5P 335109-92-7P 335109-96-1P
 335110-00-4P 335110-06-0P 335168-87-1P
 335169-20-5P 335169-31-8P 335169-96-5P
 335234-16-7P 335292-44-9P 335293-53-3P
 335600-38-9P 335600-68-5P 335603-60-6P
 336113-50-9P 336113-53-2P 336113-54-3P
 336113-55-4P 336113-56-5P 336113-57-6P
 336113-58-7P 336113-59-8P 336113-60-1P
 336113-61-2P 336113-62-3P 336113-63-4P
 336113-64-5P 336113-65-6P 336113-66-7P
 336113-67-8P 336113-68-9P 336113-69-0P
 336113-70-3P 336113-71-4P 336113-72-5P
 336113-73-6P 336113-74-7P 336113-75-8P
 336113-76-9P 336113-77-0P 336113-78-1P
 336113-79-2P 336113-80-5P 336113-81-6P
 336113-82-7P 336113-83-8P 336113-84-9P
 336113-85-0P 336113-86-1P 336113-87-2P
 336113-88-3P 336113-89-4P 336113-90-7P
 336113-91-8P 336113-92-9P 336113-93-0P
 336113-94-1P 336113-95-2P 336113-96-3P
 336113-97-4P 336113-98-5P 336113-99-6P
 336114-00-2P 336114-01-3P 336114-02-4P
 336114-03-5P 336114-04-6P 336114-06-8P
 336114-07-9P 336114-08-0P 336114-09-1P
 336114-10-4P 336114-11-5P 336114-12-6P
 336114-13-7P 336114-14-8P 336114-15-9P
 336114-16-0P 336114-17-1P 336114-18-2P
 336114-19-3P 336114-20-6P 336114-21-7P
 336114-22-8P 336114-23-9P 336114-24-0P
 336114-25-1P 336114-26-2P 336114-27-3P
 336114-28-4P 336114-29-5P 336114-30-8P
 336114-31-9P 336114-32-0P 336114-33-1P
 336114-34-2P 336114-36-4P 336114-38-6P
 336114-41-1P 336114-43-3P 336114-45-5P
 336114-47-7P 336114-49-9P 336114-51-3P
 336114-54-6P 336114-58-0P 336114-63-7P
 336114-65-9P 336114-73-9P 336114-77-3P
 336114-80-8P 336114-82-0P 336114-84-2P
 336114-87-5P 336114-89-7P 336114-91-1P
 336114-93-3P 336114-95-5P 336114-98-8P
 336115-00-5P 336115-02-7P 336115-04-9P
 336115-06-1P 336115-09-4P 336115-11-8P


336115-13-0P 336115-15-2P 336115-17-4P
 336115-19-6P 336115-22-1P 336115-24-3P
 336115-26-5P 336115-28-7P 336115-30-1P
 336115-32-3P 336115-34-5P 336115-36-7P
 336115-38-9P 336115-40-3P 336115-42-5P
 336115-44-7P 336115-46-9P 336115-48-1P
 336115-50-5P 336115-52-7P 336115-54-9P
 336115-56-1P 336115-58-3P 336115-60-7P
 336115-62-9P 336115-64-1P 336115-66-3P
 336115-68-5P 336115-70-9P 336115-72-1P
 336115-74-3P 336115-76-5P 336115-78-7P
 336115-80-1P 336115-82-3P 336115-84-5P
 336115-86-7P 336115-88-9P 336115-90-3P
 336115-92-5P 336115-95-8P 336115-97-0P
 336115-99-2P 336116-01-9P 336116-03-1P
 336116-05-3P 336116-07-5P 336116-09-7P
 336116-11-1P 336116-13-3P 336116-15-5P
 336116-17-7P 336116-19-9P 336116-21-3P
 336116-23-5P 336116-25-7P 336116-27-9P
 336116-29-1P 336116-31-5P 336116-33-7P
 336116-35-9P 336116-37-1P 336116-39-3P
 336116-41-7P 336116-43-9P 336116-45-1P
 336116-47-3P 336116-49-5P 336116-51-9P
 336116-53-1P 336116-55-3P 336116-57-5P
 336116-59-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(prepn. of N-acylquinazolinonealkylamines as **KSP** kinesin
 inhibitors)


RN 288261-76-7 CAPLUS

CN Propanamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-
 quinazolinyl]ethyl]-N-(3-methylphenyl)- (9CI) (CA INDEX NAME)



RN 288261-77-8 CAPLUS


CN Butanamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-
 N-(2-methylphenyl)- (9CI) (CA INDEX NAME)



09/ 724,941


RN 289672-01-1 CAPLUS

CN 2-Propenamide, N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-3-phenyl-N-propyl- (9CI) (CA INDEX NAME)




RN 299444-93-2 CAPLUS

CN Tetradecanamide, N-[1-(3,4-dihydro-3-methyl-4-oxo-2-quinazolinyl)ethyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)




RN 299446-39-2 CAPLUS

CN Benzamide, 4-chloro-N-[1-[3,4-dihydro-3-(2-methoxyethyl)-4-oxo-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)





RN 299446-79-0 CAPLUS

CN 2-Naphthalenecarboxamide, N-[1-[3,4-dihydro-3-(2-methoxyethyl)-4-oxo-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 336116-59-7 CAPLUS

CN 2-Quinolinecarboxamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



IT 336116-61-1P 336116-63-3P 336116-65-5P
 336116-67-7P 336116-69-9P 336116-71-3P
 336116-73-5P 336116-75-7P 336116-77-9P
 336116-79-1P 336116-81-5P 336116-83-7P
 336116-85-9P 336116-87-1P 336116-89-3P
 336116-91-7P 336116-93-9P 336116-95-1P
 336116-97-3P 336116-99-5P 336117-01-2P
 336117-03-4P 336117-05-6P 336117-07-8P
 336117-09-0P 336117-11-4P 336117-13-6P
 336117-15-8P 336117-17-0P 336117-19-2P
 336117-21-6P 336117-24-9P 336117-26-1P
 336117-28-3P 336117-30-7P 336117-32-9P
 336117-34-1P 336117-36-3P 336117-38-5P
 336117-40-9P 336117-42-1P 336117-44-3P
 336117-46-5P 336117-48-7P 336117-50-1P
 336117-52-3P 336117-54-5P 336117-56-7P
 336117-58-9P 336117-60-3P 336117-62-5P
 336117-65-8P 336117-67-0P 336117-69-2P
 336117-71-6P 336117-74-9P 336117-76-1P
 336117-78-3P 336117-80-7P 336117-82-9P
 336117-84-1P 336117-86-3P 336117-88-5P
 336117-90-9P 336117-92-1P 336117-94-3P
 336117-96-5P 336117-98-7P 336118-02-6P
 336118-04-8P 336118-06-0P 336118-09-3P
 336118-12-8P 336118-16-2P 336118-18-4P
 336118-20-8P 336118-22-0P 336118-24-2P
 336118-27-5P 336118-30-0P 336118-32-2P
 336118-34-4P 336118-36-6P 336118-39-9P
 336118-43-5P 336118-45-7P 336118-47-9P
 336118-49-1P 336118-51-5P 336118-53-7P


336118-55-9P 336118-57-1P 336118-59-3P
 336118-61-7P 336118-64-0P 336118-66-2P
 336118-68-4P 336118-70-8P 336118-72-0P
 336118-74-2P 336118-76-4P 336118-78-6P
 336118-80-0P 336118-82-2P 336118-85-5P
 336118-88-8P 336118-91-3P 336118-93-5P
 336118-95-7P 336118-97-9P 336118-99-1P
 336119-03-0P 336119-05-2P 336119-07-4P
 336119-11-0P 336119-15-4P 336119-17-6P
 336119-19-8P 336119-21-2P 336119-23-4P
 336119-25-6P 336119-27-8P 336119-29-0P
 336119-31-4P 336119-33-6P 336119-35-8P
 336119-37-0P 336119-39-2P 336119-40-5P
 336119-41-6P 336119-42-7P 336119-43-8P
 336119-44-9P 336119-45-0P 336119-46-1P
 336119-47-2P 336119-48-3P 336119-49-4P
 336119-50-7P 336119-51-8P 336119-52-9P
 336119-53-0P 336119-54-1P 336119-55-2P
 336119-56-3P 336119-57-4P 336119-58-5P
 336119-59-6P 336119-60-9P 336119-61-0P
 336119-62-1P 336119-63-2P 336119-64-3P
 336119-65-4P 336119-66-5P 336119-67-6P
 336119-68-7P 336119-69-8P 336119-70-1P
 336119-71-2P 336119-72-3P 336119-73-4P
 336119-74-5P 336119-75-6P 336119-76-7P
 336119-77-8P 336119-78-9P 336119-79-0P
 336119-80-3P 336119-81-4P 336119-82-5P
 336119-83-6P 336119-84-7P 336119-85-8P
 336125-01-0P 383191-98-8P 383192-12-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(prepn. of N-acylquinazolinonealkylamines as **KSP** kinesin
 inhibitors)

RN 336116-61-1 CAPLUS



CN Benzamide, 4-bromo-N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-
 quinazolinyl]propyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX
 NAME)



RN 336116-63-3 CAPLUS


CN Benzamide, 3,4-dichloro-N-[1-(7-chloro-3-ethyl-3,4-dihydro-4-oxo-2-
 quinazolinyl)propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)

09/ 724,941




RN 336116-65-5 CAPLUS

CN Benzamide, 3,4-dichloro-N-[1-[3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]ethyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 336116-67-7 CAPLUS



CN Benzamide, N-[1-[7-chloro-3,4-dihydro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 336116-69-9 CAPLUS

CN Benzamide, 4-bromo-N-[1-[3,4-dihydro-7-methyl-4-oxo-3-(phenylmethyl)-2-quinazolinyl]propyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)

09/ 724,941



IT 336119-86-9DP, resin bound 336119-87-0P


336119-90-5P 383192-88-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of N-acylquinazolinonealkylamines as **KSP** kinesin inhibitors)


RN 336119-86-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-[1-[(3-aminopropyl)amino]propyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 336119-87-0 CAPLUS


CN 4(3H)-Quinazolinone, 2-(1-aminopropyl)-7-chloro-3-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 336119-90-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-[1-[[2-(dimethylamino)ethyl]amino]propyl]-3-(phenylmethyl)- (9CI) (CA INDEX NAME)

09/ 724,941




RN 383192-88-9 CAPLUS

CN 4(3H)-Quinazolinone, 2-(1-aminopropyl)-7-chloro-3-(phenylmethyl)-,
(2S,3S)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336119-87-0

CMF C18 H18 Cl N3 O




CM 2

CRN 147-71-7

CMF C4 H6 O6

CDES 1:S2:R*,R*

Absolute stereochemistry.



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:869018 CAPLUS

DOCUMENT NUMBER: 136:700

TITLE: Allosteric inhibitors of pyruvate kinase for
therapeutic use

INVENTOR(S): Abraham, Donald J.; Wang, Changging; Danso-Danquah,
Richmond; Burnett, James C.; Joshi, Gajanan S.;
Hoffman, Steven J.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 15 pp., Cont.-in-part of U.S.
6,214,879.

CODEN: USXXCO

09/ 724,941

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2001046997	A1	20011129	US 2001-799873	20010307
US 6214879	B1	20010410	US 1998-46643	19980324

PRIORITY APPLN: INFO.: US 1998-46643 A2 19980324


AB Chem. structures have been identified which allosterically modify pyruvate kinase and inhibit enzymic activity. These compds. can be used as pharmaceuticals in the treatment of a wide variety of diseases and disorders where influencing metabolic processes is beneficial, e.g. the glycolytic pathway, all pathways which use ATP as an energy source, and all pathways which involve 2,3-diphosphoglycerate related to the delivery of oxygen by modifying Hb's oxygen affinity, treatments of tumor and **cancer** and Alzheimer's disease. Prepn. of e.g. 2-phenylethyloxy-5-formylbenzoic acid is described.

IT 375823-98-6

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pyruvate kinase allosteric inhibitors for therapeutic use)

RN 375823-98-6 CAPLUS

CN 3(4H)-Quinazolinepropanoic acid, 2-[1-[[[(3-chlorophenyl)amino]carbonyl](3-hydroxyphenyl)amino]ethyl]-4-oxo- (9CI) (CA INDEX NAME)



L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:798224 CAPLUS

DOCUMENT NUMBER: 135:357937

TITLE: Quinazolinone derivatives as inhibitors of human phosphatidylinositol 3-kinase delta

INVENTOR(S): Sadhu, Chanchal; Dick, Ken; Treiberg, Jennifer; Sowell, C. Gregory; Kesicki, Edward A.; Oliver, Amy

PATENT ASSIGNEE(S): Icos Corporation, USA

SOURCE: PCT Int. Appl., 278 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001081346	A2	20011101	WO 2001-US13315	20010424
WO 2001081346	A3	20020321		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,

09/ 724,941

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:


US 2000-199655P P 20000425

US 2000-238057P P 20001005

OTHER SOURCE(S):

MARPAT 135:357937

GI



AB Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3K.delta.) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3K.delta. plays a role in leukocyte function are claimed. Preferably, the methods employ active agents that selectively inhibit PI3K.delta., while not significantly inhibiting activity of other PI3K isoforms. Compds. are provided that inhibit PI3K.delta. activity, including compds. that selectively inhibit PI3K.delta. activity. The compds. claimed are all quinazolin-4-one derivs., including I [Y = null, S, NH; R = H, halo, OH, OMe, Me, CF3; R1 = H, OMe, halo; RR1 together with C-6 and C-7 of quinazoline ring define a 5- or 6-membered arom. ring optionally contg. .gtoreq. 1 O, N or S; R2 = C1-6 alkyl, Ph, halophenyl, alkylphenyl, biphenyl, PhCH2, pyridinyl, 4-methylpiperazinyl, CO2Et, morpholinyl; R3 = NH2, halo, C1-3 alkyl, S(C1-3 alkyl), OH, NH(C1-3 alkyl), N(C1-3 alkyl)2, NH(C1-3 alkylenephenyl); q = 1, 2] and pharmaceutically acceptable salts and solvates thereof. Methods of using PI3K.delta. inhibitory compds. to inhibit **cancer** cell growth or **proliferation** are also provided. Accordingly, the invention provides methods of using PI3K.delta. inhibitory compds. to inhibit PI3K.delta.-mediated processes in vitro and in vivo. Thus, in an example, dose-dependent decrease in histamine release from basophils when stimulated with anti-IgE was 100% at 1,000 nM, with an EC50 of about 25 nM for I (Y = S, R = 5-Me, R1 = H, R2 = 2-ClC6H4, R3 = H; S connected to 6-position of purine ring; prepn. given).

IT 371243-12-8P 371243-13-9P 371243-14-0P
371243-15-1P 371243-17-3P 371243-18-4P
371243-22-0P 371243-23-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. and inhibition of human phosphatidylinositol kinase by)

RN 371243-12-8 CAPLUS


CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)

09/ 724,941




RN 371243-13-9 CAPLUS

CN 4(3H)-Quinazolinone, 3-(2-chlorophenyl)-5-fluoro-2-[(1H-purin-6-ylamino)methyl]- (9CI) (CA INDEX NAME)



RN 371243-14-0 CAPLUS


CN 4(3H)-Quinazolinone, 2-[[[(2-amino-1H-purin-6-yl)amino]methyl]-5-methyl-3-(2-methylphenyl)- (2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 371243-15-1 CAPLUS


CN 4(3H)-Quinazolinone, 2-[[[(2-amino-1H-purin-6-yl)amino]methyl]-3-(2-chlorophenyl)-5-fluoro- (9CI) (CA INDEX NAME)

09/ 724,941




RN 371243-17-3 CAPLUS

CN 4(3H)-Quinazolinone, 2-[[[(2-fluoro-1H-purin-6-yl)amino]methyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 371243-18-4 CAPLUS


CN Acetamide, N-[[[3-(2-chlorophenyl)-5-fluoro-3,4-dihydro-4-oxo-2-quinazolinyl]methyl]-2-(1H-purin-6-ylthio)- (9CI) (CA INDEX NAME)



RN 371243-22-0 CAPLUS


CN 4(3H)-Quinazolinone, 2-[1-[(2-fluoro-1H-purin-6-yl)amino]ethyl]-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)

09/ 724,941



RN 371243-23-1 CAPLUS

CN 4(3H)-Quinazolinone, 5-methyl-3-(2-methylphenyl)-2-[1-(1H-purin-6-ylamino)ethyl]- (9CI) (CA INDEX NAME)




IT 371244-07-4P 371244-08-5P 371244-09-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and substitution reaction of, with chloropurine derivs.)

RN 371244-07-4 CAPLUS


CN 4(3H)-Quinazolinone, 2-(aminomethyl)-5-methyl-3-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 371244-08-5 CAPLUS

CN 4(3H)-Quinazolinone, 2-(aminomethyl)-3-(2-chlorophenyl)-5-fluoro- (9CI) (CA INDEX NAME)

09/ 724,941





RN 371244-09-6 CAPLUS
CN 4(3H)-Quinazolinone, 2-(1-aminoethyl)-5-methyl-3-(2-methylphenyl)- (9CI)
(CA INDEX NAME)



L7 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 2000:608742 CAPLUS
DOCUMENT NUMBER: 133:207917
TITLE: Preparation of anticancer dihydroquinazoline derivatives with a non-folate dependent locus of activity
INVENTOR(S): Skelton, Lorraine; Bavetsias, Vassilis; Jackman, Ann
PATENT ASSIGNEE(S): Cancer Research Campaign Technology Ltd., UK
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000050417	A1	20000831	WO 2000-GB655	20000224
W: AU, CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1155012	A1	20011121	EP 2000-905212	20000224
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.:		GB 1999-4275	A	19990224
		WO 2000-GB655	W	20000224
OTHER SOURCE(S):		MARPAT 133:207917		
GI				



AB The title compds. (I) [wherein R1 and R1' together = :O and R2 = H, alkyl, alkyl-CO-B, alkyl-CO-alkyl-B, alkyl-CO2-alkyl-B, alkyl-CO2-alkenyl-B, or alkyl-CONH-alkyl-B; B = CO2H, OH, alkoxy, NH2, (di)alkylamino, or 5- or 6-membered heterocyclic group; or R1' and R2 together = a bond and R1 is alkylthio, NHR', or NHCOR'; R' = aryl or alkyl; R3 = (CH2)_pA; p = 1-4; A = 5- or 6-membered N-contg. heterocyclic ring attached via the N or NA'A"; A' and A" = independently alkyl groups; R4 = H, :O, or alkyl and R5 = H, alkyl, or halo; or R4 and R5 together with the carbon atoms to which they are attached = 5- or 6-membered carbocyclic ring; X1 and X2 = independently O, S, or NR"; R" = H, alkyl, alkenyl, or alkynyl; Y = divalent (hetero)aryl; R6 = H, :O, or alkyl; m = 1-4; R7 = pyridyl, pyrimidyl, (alkyl)imidazolyl, or (alkyl)triazolyl], and pharmaceutically acceptable salts thereof, were prepd. for the treatment or prevention of **cancer**. I have a different pattern of activity to known chemotherapeutic agents, which operate via inhibition of thymidylate synthase (TS), and are thought to act via a new, non-folate dependent locus like that of CB30865. For example, hydrolysis of the 4-[N-(dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]benzoate tert-Bu ester (multi-step prepn. given) with TFA in CH2Cl2, followed by amidation with 3-(aminomethyl)pyridine in DMF using PyBOP.RTM. in the presence of diisopropylethylamine, gave II (70%). II inhibits TS poorly compared to the known anticancer agent CB3717 (IC₅₀ II / IC₅₀ CB3717 > 2500). However, II (CB300919) was active against the W1L2 and W1L2:C1 cell lines, including W1L2 cells incubated in the presence of folate metabolites, with IC₅₀ values of 0.49 nM, 0.28 nM, and 0.32 nM, resp. In a test against W1L2:R865, a CB30865 resistant cell line, II showed decreased activity with an IC₅₀ of 13,000 nM. In addn., II demonstrated antitumor activity against CH1 ovarian and HT29 colon **cancer** cells in nude mice at doses that were tolerated.

IT **289715-29-3P**, CB 300922


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(anticancer agent; prepn. of anticancer 6-[N-(4-carbamoylphenyl)-N-(prop-2-ynyl)amino]methyl]-3,4-dihydroquinazolin-4-ones by hydrolysis and amidation of 4-[N-(dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]benzoate tert-Bu esters)

RN **289715-29-3** CAPLUS

09/ 724,941

CN Benamide, 4-[[[7-chloro-2-[(diethylamino)methyl]-3,4-dihydro-3-methyl-4-oxo-6-quinazolinyl]methyl]-2-propynylamino]-N-(3-pyridinylmethyl)- (9CI)
(CA INDEX NAME)




IT 289686-91-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; prepn. of anticancer 6-[[N-(4-carbamoylphenyl)-N-(prop-2-ynyl)amino]methyl]-3,4-dihydroquinazolin-4-ones by hydrolysis and amidation of 4-[N-(dihydroquinazolin-6-ylmethyl)-N-(prop-2-ynyl)amino]benzoate tert-Bu esters)

RN 289686-91-5 CAPLUS

CN Benzoic acid, 4-[[[7-chloro-2-[(diethylamino)methyl]-3,4-dihydro-3-methyl-4-oxo-6-quinazolinyl]methyl]-2-propynylamino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 10:36:56 ON 22 JUL 2002)

FILE 'REGISTRY' ENTERED AT 10:37:20 ON 22 JUL 2002

L1 STRUCTURE UPLOADED

L2 50 S L1

L3 36714 S L1 FUL

FILE 'CAPLUS' ENTERED AT 10:39:42 ON 22 JUL 2002

L4 248 S L3

L5 21 S L4 AND (CARBONYL OR CARBOXAMID? OR SULFON?)

L6 6 S L4 AND (PROLIFERATI? OR KSP OR CANCER? OR HYPERPLASIA)

L7 5 S L6 NOT L5

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

128.28	269.91
--------	--------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

09/ 724,941

CA SUBSCRIBER PRICE

-16.11

-16.11

STN INTERNATIONAL LOGOFF AT 10:43:47 ON 22 JUL 2002